Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 100 Publications

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344

Nature, 2011, 471(7337):235-9

PubMed: 21390130

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006

Cell, 2014, 158(5):989-99

PubMed: 25131989

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305

Nat Commun, 2014, 5:3361

PubMed: 24553445
Blood, 2013, 123(5):706-16

PubMed: 24319254

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941
EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642
Sci Signal, 2010, 3(146):ra80

PubMed: 21045206

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394

Cancer lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed:

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545

Int J Cancer, 2015, 136(11):2717-29

PubMed:

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732

Cell Death Dis, 2013, 4:e733

PubMed: 23868066
Cell Death Dis, 2013, 4:e951

PubMed: 24309938

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed:

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed:

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401

Br J Haematol, 2015, 168(3):371-83

PubMed:

J Biol Chem, 2015, 290(8):5028-40

PubMed:

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624
J Biol Chem, 2012, 287(43):36609

PubMed: 22952229

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454

J Transl Med, 2011, 9:37

PubMed: 21477288

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462
Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916

Blood Cancer J, 2015, 5:e312

PubMed: 25978432

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956

BMC Cancer, 2015, 15(1):273

PubMed: 25880212

BMC Cancer, 2014, 14(1):373

PubMed: 24886166

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617

PLoS One, 2013, 8(1):e53766

PubMed: 23320102

PLoS One, 2012, 7(9):e44265

PubMed: 22957056

PLoS One, 2012, 7(12):e52335

PubMed: 23272238

PLoS One, 2012, 7(12):e52753

PubMed: 23300762

PLoS One, 2011, 6(7):e22739

PubMed: 21818379

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750
FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed:

BMC Neurosci, 2011, 12:50

PubMed: 21615950

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606
Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed:

20 Customer Reviews

Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.

Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.
Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.
Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.
Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.

D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.
IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m^-/-mice were injected s.c. with 1×10⁶ MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b²)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch^,scorrection and a Mann-Whitney U test.

Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.
SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.
SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.
(a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

(a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.
(a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.
Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	NVzpXmpkU2mwYYPlJGF{e2G7		MXWxJIg>	Mof5SG1UVw>?	NF\OOJZidnSrLVjERWMyKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEyOiEQvF2=	MkT0NVE6PjB2OEm=
Friend leukemic cell	NIfzOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLlOVAh\|ryP	M3jhTlczKGh?	NYDZb\|Z6TE2VTx?=	MVvJR\|UxRTBwOUmg{txO	MkGwNVIyODl7MUO=
K562	MkXMT4lv[XOnIFHzd4F6		M{jlUVYhcA>?	MornSG1UVw>?	M2Pp[GlvcGmkaYTpc44hd2ZiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SBqbXn4eJVz\SCxZjDISGFEOSCjbnSgTGRCSzJrIIfpeIghUUN3MDDv[kAxNjBzIN88US=>	MYKxNlQyQTN6MB?=
HT1080	MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoHuO\|IhcA>?	M{fDVmROW09?	MlnuTWM2OD1{LkSg{txO	MXWxNlI4ODF5NR?=
H1299	NX;YSIZYU2mwYYPlJGF{e2G7		NVWx[4pyOjBibXnu	NGj3T3pFVVOR	MWPJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgTGRCSyCnbor5cYUhf2m2aDDJR\|UxKG:oIECuNVk1KM7:TR?=	M{LpeVE1PTJzNEKy
H1299	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVzPN\|VrPzJiaB?=	MVLEUXNQ	NXHZW4FMUUN3ME23MlI1KM7:TR?=	MW[xOFUzOTR{Mh?=
HeLa	MWDLbY5ie2ViQYPzZZk>		NXjKeoVOOzBibXnu		MkXCTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaHnzeI9v\SCmZXHj[ZR6dGG\|ZTD3bZRpKEmFNUCgc4YhOC5{ODFOwG0>	MYOxOVYxOzl2OR?=
LOX-IMVI	NHvmRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXy0PEBp		M3HPWGlEPTB;MT6zJO69VQ>?	MUmxOVcyPTR5MB?=
NCI-H226	NWjldo53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NInKd5Y1QCCq		M{izeWlEPTB;Mj62JO69VQ>?	NULGVlFwOTV5MUW0O\|A>
RXF-631L	MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLJV3E1QCCq		NFXtTohKSzVyPUKg{txO	MkHjNVU4OTV2N{C=
SNB-78	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmTZOFghcA>?		NV7aS2pyUUN3ME2xOkDPxE1?	MV[xOVcyPTR5MB?=
St-4	M2nKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4rlflQ5KGh?		NEjPXHBKSzVyPUWuNkDPxE1?	M3r0WVE2PzF3NEew
ARP1	MmjtSpVv[3Srb36gRZN{[Xl?	NFTTSZEzKM7:TR?=	NUH4enU3PiCq		NVft[4ZVUW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	NV;rdGt3OTR5M{S4NFY>
CEM	NH3jVoNMcW6jc3WgRZN{[Xl?		NH7HV5YyKGh?	NELIfoJFVVOR	M2LmdmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1?	NFjsXnEyPjR{MEC2OC=>
HCT15	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{TxbVQ5KGh?		MmTNS2k2OD1yLkiyJO69VQ>?	M{nSelE3PzJ\|MkK3
NCI-H23	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYW0PEBp		NGKz[GRIUTVyPUCuPVIh\|ryP	MnixNVY4OjN{Mke=
GM15850	MXXLbY5ie2ViQYPzZZk>	MVGyMlUh\|ryP	NES1V2w6PiCq	MnTvSG1UVw>?	NX[3c3NkUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NGD3NnYyPjl{MUO2Oy=>
GM15850	MmfUT4lv[XOnIFHzd4F6	MorENk42KM7:TR?=	Mm\wPVYhcA>?	NEWwNFhFVVOR	NWr0PIp3UW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MVyxOlkzOTN4Nx?=
GM15850	NWX0TVlbU2mwYYPlJGF{e2G7	NXzwUpZVOi53IN88US=>	MXm5OkBp	MV\EUXNQ	MUjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMUKgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	NFXjNIEyPjl{MUO2Oy=>
GM15850	MVfLbY5ie2ViQYPzZZk>	NVLwdVdiOi53IN88US=>	MkW5PVYhcA>?	NIXt[JBFVVOR	NXnpNoRKUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MX:xOlkzOTN4Nx?=
GM15850	MWLLbY5ie2ViQYPzZZk>	NGX1eIszNjVizszN	Ml\jPVYhcA>?	Ml3CSG1UVw>?	MVLJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViODDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	NH\veIcyPjl{MUO2Oy=>
GM15850	Ml;OT4lv[XOnIFHzd4F6	M1vjUFIvPSEQvF2=	NHrsboU6PiCq	NYnOfmNXTE2VTx?=	MXLJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViMU[gZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?	NVTLW\|RyOTZ7MkGzOlc>
U937	Mm[0SpVv[3Srb36gRZN{[Xl?	Mo\zOUDPxE1?	NUDMToExOjRiaB?=	MXfEUXNQ	MVjD[YxtKGO7Y3zlJIFzemW\|dDDifUBi[2O3bYXsZZRqd25iYYSgV{9IOi:PIIDoZZNm	NH;PTHEyPzByNEexPC=>
H661	NWi5NmtpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkHjOFghcA>?		NH\NTldKSzVyPUGg{txO	NV3yeVN3OTdzNUewNFk>
U937	MXHGeY5kfGmxbjDBd5NigQ>?	M{i0dVUh\|ryP	NI\nOZQzPCCq	MoLySG1UVw>?	MX;JcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w	MVSxO\|Q1Pzd3MB?=
U937	NF\oNZFHfW6ldHnvckBCe3OjeR?=	NWHHVnNEOSEQvF2=	NGjyNVkzPCCq	MnHDSG1UVw>?	NYS5fZBITW[oZXP0JI9vKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44>	NUPvc3o2OTd2NEe3OVA>
RAW264.7	M33jcmZ2dmO2aX;uJGF{e2G7	M136elExKM7:TR?=	NEOzZngzPGh?	MYP3ZZRmeg>?	NF7KTWVKdmirYnn0bY9vKG:oIFzQV{1{fGmvdXzheIVlKFSQRnHsdIhiKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvPzZizszN	M1vEXFE4PDd5NUG4
RAW264.7	NXrjU\|VwTnWwY4Tpc44hSXO\|YYm=	MWOxNEDPxE1?	NYXYbnJSOjSq	MWL3ZZRmeg>?	NWT6R4J[UW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCQTzDwdo9lfWO2aX;uJJdqfGhiSVO1NEBw\iBzLki4JO69VQ>?	M3jiOVE4PDd5NUG4
SC9	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlfQOFghcA>?		Ml36TWM2OD1yLk[wOkDPxE1?	M2rFT\|E4PTB5MkG5
ST14A	NIr4eHhHfW6ldHnvckBCe3OjeR?=	MmjFOUBvVQ>?	MnvmO\|IhcA>?		NITndGRKdmO{ZXHz[UBqdiCURWPUM25TW0ZibWLORUBmgHC{ZYPzbY9v	NIjhNJkyPzV4NUm5Ny=>
ST14A	NFXqd2VHfW6ldHnvckBCe3OjeR?=	MX61JI5O	NHTqeZI4OiCq		NUDHcXJ7UW6lcnXhd4UhcW5iRULGNUBuWk6DIHX4dJJme3Orb36=	NF3ENpUyPzV4NUm5Ny=>
PANC1	NY\lcY8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnqSYt3OSEQvF2=			M322XGlEPTB;MD60OUDPxE1?	MUCxO\|U5QDd2NB?=
PANC1	MoTaSpVv[3Srb36gRZN{[Xl?	M2PW[VEh\|ryP	MYeyOEBp		NVjWdJc3UW6lcnXhd4UhcW5icEKxW2FHOS:FSWCxJIdmdmViZYjwdoV{e2mxbh?=	NFiyblQyPzV6OEe0OC=>
PANC1	M3HQW2Z2dmO2aX;uJGF{e2G7	MnS0NUDPxE1?	MmfLNlQhcA>?		MnLuTY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	NF\1e3cyPzV6OEe0OC=>
PT45	M4LGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTRizszN	MUexO\|U5QDd2NB?=
ACHN	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUSyNUBp		NXjSR4JST0l3ME2wMlY2KM7:TR?=	MUCxO\|Y3OjZyNh?=
PC3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M13ZOlIyKGh?		MnPzS2k2OD1yLkexJO69VQ>?	MmnSNVc3PjJ4ME[=
A431	MnThR5l1d3SxeHnjJGF{e2G7		Moq0O\|IhcA>?		NVfhT2dtUUN3ME20MlIh\|ryP	NHfUUYgyPzZ7MUe2Ny=>
Cal27	NUPFT5ZYS3m2b4TvfIlkKEG\|c3H5		NUOwVVdxPzJiaB?=		MnPpTWM2OD1\|LkKg{txO	MkW2NVc3QTF5NkO=
CCRF-CEM	NED6R3FEgXSxdH;4bYMhSXO\|YYm=		NX31WmJXPzJiaB?=		NXPFbpZIUUN3ME2wMlgh\|ryP	NUC1fJJzOTd4OUG3OlM>
EOL1	M2\qfGN6fG:2b4jpZ{BCe3OjeR?=		MWW3NkBp		M2raTGlEPTB;MTFOwG0>	NGXiU5cyPzZ7MUe2Ny=>
Hec-1-A	NVzUWpJFS3m2b4TvfIlkKEG\|c3H5		NHjQV5M4OiCq		Mmq3TWM2OD1zIN88US=>	MUOxO\|Y6OTd4Mx?=
HeLa	NUXaSo9xU2mwYYPlJGF{e2G7	MYCxNEDPxE1?	NIDOVG0{OCCvaX6=	MnTXSG1UVw>?	MYnJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWMyKHerdHigTWM2OCCxZjCwMlAzKM7:TR?=	MUSxO\|Y6OTd4Mx?=
RKOp21	NX25Tm9[S3m2b4TvfIlkKEG\|c3H5		MWm3NkBp		NHzNV21KSzVyPUGuO\|Yh\|ryP	Ml;LNVc3QTF5NkO=
Saos2	MWfDfZRwfG:6aXOgRZN{[Xl?		MmXZO\|IhcA>?		M1e0WWlEPTB;Mj6zJO69VQ>?	MXuxO\|Y6OTd4Mx?=
SK-OV-3	NU[wNVFpS3m2b4TvfIlkKEG\|c3H5		NXnUc3k2PzJiaB?=		MUHJR\|UxRTJwMjFOwG0>	NVTxT5V1OTd4OUG3OlM>
U87MG	NFrDS5pEgXSxdH;4bYMhSXO\|YYm=		NWHvRlI3PzJiaB?=		MV7JR\|UxRTFzIN88US=>	Mn;jNVc3QTF5NkO=
NUGC3	NUXrR4c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfk[lY2KM7:TR?=	MUSyOEBp		NHnYZmNIUTVyPUKuO\|kh\|ryP	Mn3lNVc6ODR6NEO=
CCD1059SK	M2G5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXhZ5FKSzVyPUSzMlUh\|ryP	NE\oWZoyQDJ2N{W1OC=>
HepG2	MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFK0UnpKSzVyPUCuNFAxPiEQvF2=	NIDrV4YyQDJ2N{W1OC=>
HT1080	M{HPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPNTWM2OD1yLkCwNlQh\|ryP	Mkj3NVgzPDd3NUS=
SKBR3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTxXXZZUUN3ME2wMlgh\|ryP	NISzTokyQDJ2N{W1OC=>
SNB78	NFLCR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjFR\|UxRTF4IN88US=>	MYmxPFI1PzV3NB?=
SQ20B	MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTNizszN	NXjl[lRpOTh{NEe1OVQ>
St4	M2jOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHOxVJdGSzVyPUWuNkDPxE1?	MYOxPFI1PzV3NB?=
MCF7	Ml;6SpVv[3Srb36gRZN{[Xl?	NWHvPHE4OTBizszN	MWW4JIg>	MlnMSG1UVw>?	MUfJcoR2[3Srb36gc4YhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u	NI\tR3IyQDJ4OUKyOi=>
HEK293	NH3JbFZMcW6jc3WgRZN{[Xl?		M3\Y[VEhcA>?	NWPjPJFxTE2VTx?=	NG[4b29KdmirYnn0bY9vKG:oIFjERWMyKHerdHigTWM2OCCxZjCwMlA{KM7:TR?=	MVOxPFMxQDV4Mx?=
HEK293	NXXGVmNlU2mwYYPlJGF{e2G7		MXWxJIg>	MmHRSG1UVw>?	NFz3TnBKdmirYnn0bY9vKG:oIFjERWM{KHerdHigTWM2OCCxZjCwMlA2PyEQvF2=	M2O1[FE5OzB6NU[z
G401	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUnoWG1lPzJiaB?=	M4nFXmROW09?	NX:2TlNxUUN3ME2xJO69VQ>?	NH31fFYyQDN5MEO3Ny=>
HeLa	NFPNZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NETlTXA4OiCq	Mn7xSG1UVw>?	M4XvdWlEPTB;MD60OkDPxE1?	MkXPNVg{PzB\|N{O=
Human renal epithelial cell	NV;he491T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUf1[3dVPzJiaB?=	NX25Om96TE2VTx?=	MofjTWM2OD1zNDFOwG0>	NUjYUIplOTh\|N{CzO\|M>
U937	MVPGeY5kfGmxbjDBd5NigQ>?	NV24N45jPSEQvF2=	M1rEVVI1KGh?		M1zZSWlv\HWldHnvckBw\iCqaYP0c45mKEh2IHj5dIVz[WOndInsZZRqd25?	M1LIblE5OzhzMkO4
U937	MVjGeY5kfGmxbjDBd5NigQ>?	NGPDNFE2KM7:TR?=	NUnnN3NsOjRiaB?=		NEDlcndKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u	NGLrd\|kyQDN6MUKzPC=>
U937	NF75UZVHfW6ldHnvckBCe3OjeR?=	MlvhOUDPxE1?	Mlv5NlQhcA>?		M37pRWlv\HWldHnvckBw\iCyMkGg[ZhxemW\|c3nvci=>	NYTxZ2FOOTh\|OEGyN\|g>
U937	NGTpbnJHfW6ldHnvckBCe3OjeR?=	M3jMR\|Uh\|ryP	MUOyOEBp		MWLJcoR2[3Srb36gc4Yh[XCxcITvd4l{	NV;yd4p[OTh\|OEGyN\|g>
U937	MlrvSpVv[3Srb36gRZN{[Xl?	MXi1JO69VQ>?	M3;SVlI1KGh?		MUTJcoR2[3Srb36gc4Yh\3KjboXsc4N6fGmlIHTp[oZmemWwdHnheIlwdg>?	MmHNNVg{QDF{M{i=
U937	NWf2fodmU2mwYYPlJGF{e2G7	NFT2d2w2KM7:TR?=	NGTwfIgzPCCq		NWrz[WFMUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDNS=>	Mn\vNVg{QDF{M{i=
U937	MXfLbY5ie2ViQYPzZZk>	M4DUZVUh\|ryP	MkPDNlQhcA>?		M3LYNWlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{S=	M2DKWlE5OzhzMkO4
HEK-TE	MULGeY5kfGmxbjDBd5NigQ>?	NX:5clFjPSEQvF2=	NUWxWFQ5Pmh?	NGDRe4VFVVOR	M333Z2lv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	NGexOZoyQDR\|NEG0OC=>
HPDE6c7	NX\4blJQS3m2b4TvfIlkKEG\|c3H5	MUW1NEDPxE1?	M{fJOlczKGh?	MVnEUXNQ	NInQPYRKSzVyPUGuN{DPxE1?	MlrxNVg1QTR2NkO=
Human microvascular epithelial cell	M{nRZWN6fG:2b4jpZ{BCe3OjeR?=	MYK1NEDPxE1?	Mn;SO\|IhcA>?	M1vaSGROW09?	MX7JR\|UxRTFwMzFOwG0>	NVnsTndMOTh2OUS0OlM>
Hup T3	NU\vemx1S3m2b4TvfIlkKEG\|c3H5	MoHEOVAh\|ryP	MUK3Nog>	MkPMSG1UVw>?	NY\2VHdIUUN3ME2wMlgh\|ryP	MWKxPFQ6PDR4Mx?=
Mia Paca2	M4CyPGN6fG:2b4jpZ{BCe3OjeR?=	NIXlW3c2OCEQvF2=	MmnYO\|Jp	NUjpUZZUTE2VTx?=	M2DwZmlEPTB;MT6xJO69VQ>?	MmTWNVg1QTR2NkO=
Panc 04.03	NUXhZ5lJS3m2b4TvfIlkKEG\|c3H5	MVG1NEDPxE1?	NFjPTZE4Omh?	NXm0RnJiTE2VTx?=	M2PmbGlEPTB;MT6yJO69VQ>?	MUWxPFQ6PDR4Mx?=
SU 86.86	NIrr[ppEgXSxdH;4bYMhSXO\|YYm=	MYS1NEDPxE1?	NYSzeWpnPzKq	NUm2dZpRTE2VTx?=	MmTvTWM2OD1zLkOg{txO	NUHSeIF[OTh2OUS0OlM>
HEK293	NVLtZpRuU2mwYYPlJGF{e2G7		NFnTTpQ{KGh?		NHLVblFKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUN4IHX4dJJme3Orb36ge4l1cCCLQ{WwJI9nKDBwMEG5JO69VQ>?	MVmxPFU2QDZ4OR?=
HeLa	M1T4R2tqdmG\|ZTDBd5NigQ>?		MU[yJIg>		M{XoXGlvcGmkaYTpc44hd2ZiboXjcIVieiCKRFHDJJdqfGhiSVO1NEBw\iByLkC4N{DPxE1?	NXvNXHQ1OTh3NUi2Olk>
RAW264.7	NYjxdXZnTnWwY4Tpc44hSXO\|YYm=	M1i5bFIh\|ryP	MoXYN{42KGh?	NXLUUoxJTE2VTx?=	MmjGRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCoYXzjbZBienWvIHnu[oVkfGWmIIfpeIghUUN3MDDv[kAxNjFzIN88US=>	NEHSd4MyQDZ2NEm2PS=>
NB4			MmPyOFhp	NHLlUpFFVVOR	NF\tcmxKSzVyPUCuOkDPxE1?	MVKxPFczOzN2OR?=
HEK293	NVvLfoc2TnWwY4Tpc44hSXO\|YYm=	MlHiNVAh\|ryP	NVTxdoVMOjRiaB?=	M1r4TmROW09?	MU\BZ5RqfmG2aX;uJI9nKG2xdYPlJHdvfDOjIIPp[45idGmwZzDlfJBz\XO\|ZXS=	MXqxPVAzOjZ5NR?=
HCT116	NUXQV\|J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH;zRmo4Omh?	MUPEUXNQ	NGX0d\|lKSzVyPUCuN\|Eh\|ryP	NXPEXWZoOTlyOESyPVQ>
HeLa	NVjPfHdSU2mwYYPlJGF{e2G7	NYfa[49mOiEQvF2=	MXuzNEBucW5?	NHLWfWdFVVOR	M2HkbWlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?=	M2HTdFE6ODh2Mkm0
IGROV1	NYPJ[pE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXjHNXFNPzJiaB?=	NWDxVG55TE2VTx?=	MXLJR\|UxRTJwMjFOwG0>	Mmj0NVkxQDR{OUS=
IGROV1	NVfuUHN7U2mwYYPlJGF{e2G7	Mki0OUDPxE1?	NYT2O5VKOjRiaB?=	MnnZSG1UVw>?	MVjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMheDV\|IHHj[ZR6dGG2aX;u	M1rUOFE6ODh2Mkm0
IGROV1	NHi5bVFMcW6jc3WgRZN{[Xl?	MoPFNVAh\|ryP	Mm\COEBp	MVnEUXNQ	NUnWUmRFUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmVvSESgZYNmfHmuYYTpc44>	NFnYS5EyQTB6NEK5OC=>
IGROV1	NWHpTlFwU2mwYYPlJGF{e2G7	M2TUVlExKM7:TR?=	NVLne49RPCCq	NWi2OmtrTE2VTx?=	M4jZRmlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXzwbIEufHWkdXzpckBi[2W2eXzheIlwdg>?	NF7X[I0yQTB6NEK5OC=>
T24	M3zFdGtqdmG\|ZTDBd5NigQ>?		MYOzJIg>		MW\JcoR2[3Srb36gc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjD3bZRpKEWFNUCgc4YhOC5zMjFOwG0>	NF\yfoMyQTB6NEO5OS=>
T24	NY\COJlsU2mwYYPlJGF{e2G7		M{PzbVMhcA>?		MVzJcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6yOUDPxE1?	MYWxPVA5PDN7NR?=
HeLa	NFXBOWNMcW6jc3WgRZN{[Xl?		MmTwNVUhdWmw	Mly0SG1UVw>?	NEDDbJdKdmirYnn0bY9vKG:oIFjERWM3KG[{b32gcpVkdGWjcjDlfJRz[WO2IIfpeIghUUN3MDDv[kAxNjB6NUWg{txO	NHzDeJgyQTB7M{i4OC=>
HeLa	NFLNbJFMcW6jc3WgRZN{[Xl?		NIfYSI4yPSCvaX6=	Mn;KSG1UVw>?	NGHDc5JKdmirYnn0bY9vKG:oIFjERWM5KG[{b32gcpVkdGWjcjDlfJRz[WO2IIfpeIghUUN3MDDv[kAyNjh4IN88US=>	NVr5XnhHOTlyOUO4PFQ>
NCI-H69	NWHNc5hyS3m2b4TvfIlkKEG\|c3H5		MkTGO\|IhcA>?	M3nwdGROW09?	M1[3PGlEPTB;Mj6wOkDPxE1?	NEnqbHYyQTB7M{i4OC=>
SKMES1	NWTCPG1DS3m2b4TvfIlkKEG\|c3H5		NHjUdVM4OiCq	NF7W[2JFVVOR	M1fSWGlEPTB;Mj60NkDPxE1?	MmfGNVkxQTN6OES=
S2	NW[3eYZtU2mwYYPlJGF{e2G7	M1Tr[lAvOS1zMDFOwG0>	Ml;TNUBp		NFrZNpNKdmirYnn0bY9vKG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBJTEGFMTDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDBwMEW5JO69VQ>?	M{fIbVE6OzF5NEWw
SHSY5Y	NIOwTXBMcW6jc3WgRZN{[Xl?	Mn7ENVAh\|ryP	M1nvblQ5KGh?	Mlm4SG1UVw>?	M2j5eGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?	MXyxPVM1PDF5NR?=
SHSY5Y	NXftOGNIS3m2b4TvfIlkKEG\|c3H5	MWOxNEDPxE1?	MV20PEBp	MX;EUXNQ	Ml;PTWM2OD1{IN88US=>	MoXsNVk{PDRzN{W=
DMS114	NGO4dZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NG\lOGE1QCCq		M3vPfWdKPTB;Mj65JO69VQ>?	M4HTS\|E6PDF7MkC1
HBC5	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\ie\|Q5KGh?		MVfHTVUxRTF5IN88US=>	M3XoTlE6PDF7MkC1
SNB78	M1HOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mof3OFghcA>?		MWrHTVUxRTF4IN88US=>	NWnVSVQ{OTl2MUmyNFU>
HeLa	NHv1NVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF\j[m04OiCq	NED3RphFVVOR	MmX4TWM2OD1yLkS2JO69VQ>?	NFXvcZAyQTR2MUi0Oi=>
BHK	NUiyZ\|ROU2mwYYPlJGF{e2G7	MnzsOUDPxE1?	MmH4NlQhcA>?	MXLEUXNQ	NF:5R5ZKdmirYnn0bY9vKG:oIFjERWM4KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBxdGG\|bXGgcYVu[nKjbnWgSoRmdHSjNUC4JGNHXFJicILveIVqdg>?	MYexPVk3Pjd6OR?=
CFBE41o-	M3HObGtqdmG\|ZTDBd5NigQ>?	MoXpOUDPxE1?	MWi4JIg>	NXm1dpl2TE2VTx?=	M4nqTGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqeYDldoFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEO=	MXSxPVk3Pjd6OR?=
CFBE41o-	NXvCXJQxU2mwYYPlJGF{e2G7	MVS1JO69VQ>?	M3TuXVQhcA>?	NEnHTIlFVVOR	MnrmTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIH31eIFvfCCIZHXseIE2ODhiQ1\UVkBxem:2ZXnuJIxmfmWu	NILwWYQyQTl4Nke4PS=>
CFBE41o-	MWjLbY5ie2ViQYPzZZk>	MYOxJO69VQ>?	NHXzN4wyKGh?	NEPvW4JFVVOR	MXrJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iQ1\UVkBxem:2ZXnuJIxmfmWu	M1m3flE6QTZ4N{i5
Primary bronchial epithelial cell	MmLZT4lv[XOnIFHzd4F6	M4HVRlEh\|ryP	NIP6dFYzPCCq	MV;EUXNQ	M3rU[WlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGGyaXPhcEB{fXKoYXPlJIxw[2GuaYrheIlwdg>?	NH\KeYQyQTl4Nke4PS=>
CFBE41o-	NH3PZ3hMcW6jc3WgRZN{[Xl?	MYqxJO69VQ>?	NYrJTYlsPSCmYYnz	NVPVeoRPTE2VTx?=	NHr6bopKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn6ZZRqd25ib3[gSoRmdHSjNUC4JGNHXFJicILveIVqdg>?	MUSxPVk3Pjd6OR?=
CFBE41o-	MWPLbY5ie2ViQYPzZZk>	M2myWFEh\|ryP	NUfESY1MOjRiaB?=	M1jQRWROW09?	Mm\vTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKHS{YX\mbYNscW6p	MlnoNVk6PjZ5OEm=
CFBE41o-	M3PwcmtqdmG\|ZTDBd5NigQ>?	MUi1JO69VQ>?	NYnGSYhCOjRiaB?=	MVzEUXNQ	NFjtWHZKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJJifGVib3[gcYF1fXKjdHnvckBw\iCFRmTSJJBzd3SnaX6geI8hcXS\|IHfsfYNw\m:{bR?=	MnPJNVk6PjZ5OEm=
CFBE41o-	M{TkVGtqdmG\|ZTDBd5NigQ>?	NXzQNW9IPSEQvF2=	NID0ZnYzPCCq	MoniSG1UVw>?	MWjJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm2eTDv[kBH\GWudHG1NFghS0[WUjDwdo91\Wmw	MkTUNVk6PjZ5OEm=
CFBE41o-	NG\IWoFMcW6jc3WgRZN{[Xl?	NGDN[YU2KM7:TR?=	M1PTPFI1KGh?	NY\oOGlrTE2VTx?=	NFHlWXRKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHPvdpJm[3Srb36gc4YhdXW2YX70JGZl\Wy2YUWwPEBETlSUIITyZYZncWOtaX7nJJRwKGOnbHygd5Vz\mGlZTDhd{BodHmlb3\vdo0>	MVSxPVk3Pjd6OR?=
Primary bronchial epithelial cell	MUTLbY5ie2ViQYPzZZk>	M{nFdlUh\|ryP	M2HnO\|I1KGh?	M4PCemROW09?	M1XhR2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v	M2PGbFE6QTZ4N{i5
Primary bronchial epithelial cell	NV3xPIVMU2mwYYPlJGF{e2G7	M{PFblEh\|ryP	NVrGW3NJQTZiaB?=	MVLEUXNQ	NXf3cYluUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{cG:{dDDjbZJkfWm2IHP1dpJmdnS\|	M37D[FE6QTZ4N{i5
BxPC3	NXrMOGxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1G5d\|czKGh?		NVTHTpdxUUN3ME2yMlch\|ryP	NF3zbIwzODF2M{e3PC=>
CAL27	M2Ll[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWK3NkBp		Mo\tTWM2OD1\|LkeyJO69VQ>?	MX2yNFE1Ozd5OB?=
Capan1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY[3NkBp		MVvJR\|UxRTdwMzFOwG0>	MonhNlAyPDN5N{i=
HCC827	NYLrR5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGfw[Wo4OiCq		M2nKUGlEPTB;MT64JO69VQ>?	NVHRN3A2OjBzNEO3O\|g>
LNCAP	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV63NkBp		MWTJR\|UxRTBwNUig{txO	MUmyNFE1Ozd5OB?=
NCI-H2122	NVTQSYdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1e4b\|czKGh?		NWjIb446UUN3ME23MlUh\|ryP	MV6yNFE1Ozd5OB?=
NCI-H358	NUfifXROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH;BXXI4OiCq		MmL3TWM2OD1{LkWg{txO	M2DrZlIxOTR\|N{e4
SCC15	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXq4c2FlPzJiaB?=		NFjpSWRKSzVyPUKuOFkh\|ryP	MnXPNlAyPDN5N{i=
SCC25	M1;KO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3nzflczKGh?		NEXIWHNKSzVyPUGuPVMh\|ryP	NFjOW3czODF2M{e3PC=>
SKHEP1	NYnqdGRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX[3NkBp		MVfJR\|UxRTNwNE[g{txO	NX\sR2Q3OjBzNEO3O\|g>
BJ	M3j5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV2xNFAh\|ryP	M{PBdVQ5KGh?	MYDEUXNQ	M{P3UWdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN	MX:yNFE1Ozh2MB?=
MUF	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nCd\|ExOCEQvF2=	MUi0PEBp	M1vLW2ROW09?	MmXlS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=	NEPiVIIzODF2M{i0NC=>
Caco-2	NVK2bId{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PBdlExOCEQvF2=	M1zEelQ5cA>?	NXPEfG1oTE2VTx?=	NFXjUGJKSzVyPUiuNUDPxE1?	NXjNO4p4OjBzNEO4OFA>
Caco-2	M3nYSWtqdmG\|ZTDBd5NigQ>?	M1zIWFUh\|ryP	MY[0JIg>	NF3oeHNFVVOR	NXrGcnJTUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm\|dH;u[UBi[2W2eXzheIlwdiCLQ{WwJI9nKDBwMEO3JO69VQ>?	NEP3VVMzODF2M{i0NC=>
Caco-2	NWP2d\|Z1U2mwYYPlJGF{e2G7	MkO5NE4{OTZibl2geI8hOzFwNjFOwG0>	M37mNlQhcA>?	NHT1eIdFVVOR	MnH5SZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzIIfpeIghUUN3MDDv[kAxNjFzOTFOwG0>	M1vBeFIxOTR\|OESw
Caco-2	M{DDWWtqdmG\|ZTDBd5NigQ>?	MYWwMlMyPiCwTTD0c{A{OS54IN88US=>	M1njWVQhcA>?	M4W0[mROW09?	M2DQeGV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMzD3bZRpKEmFNUCgc4YhOC5zNEeg{txO	M4TxclIxOTR\|OESw
Caco-2	NFThTXZMcW6jc3WgRZN{[Xl?	MXO2MlMzKG6PIITvJFY{OiEQvF2=	MnXnOEBp	M3mySWROW09?	NH;LfIpGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Wge4l1cCCLQ{WwJI9nKDF{Lk[g{txO	MmLFNlAyPDN6NEC=
Caco-2	NH;0S5BMcW6jc3WgRZN{[Xl?	M{e5fVYvOzJibl2geI8hPjN{IN88US=>	NVLWdVlzPCCq	MX7EUXNQ	M3vaeWV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNzD3bZRpKEmFNUCgc4YhPDFizszN	NULBe4VuOjBzNEO4OFA>
Caco-2	M2nW[GtqdmG\|ZTDBd5NigQ>?	M{jh[\|AvOzF4IH7NJJRwKDNzLk[g{txO	M3\OcVQhcA>?	MkDGSG1UVw>?	NUH3[3BRTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO2	MYiyNFE1Ozh2MB?=
HepG2	NFjvenVMcW6jc3WgRZN{[Xl?	MWO1JO69VQ>?	NXX4fYgyPmh?	NFjnRoZFVVOR	MXPJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	NF;WV5YzODF2M{i0NC=>
HepG2	M2HmV2tqdmG\|ZTDBd5NigQ>?	NULQRodVPSEQvF2=	MWq2bC=>	NEfxZnhFVVOR	M3HPWmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgbJlx\XKjY3X0fYxifGmxbh?=	MUSyNFE1Ozh2MB?=
HepG2	Ml3kT4lv[XOnIFHzd4F6	NUjaNZRjPSEQvF2=	M4DSeVZp	Ml3GSG1UVw>?	NGj5OWpKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBidHCqYT30eYJ2dGmwIHHj[ZR6dGG2aX;u	M{nUVVIxOTR\|OESw
HepG2	MUXLbY5ie2ViQYPzZZk>	NIGyN282KM7:TR?=	MWK2bC=>	MojiSG1UVw>?	NInkOYJKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBJOy:KNDDobZN1d26nIHHj[ZR6dGG2aX;u	MnqyNlAyPDN6NEC=
COLO205	NV7aeItnU2mwYYPlJGF{e2G7	NHGxNnQyOCEQvF2=	NWG0N5pjOjRiaB?=	NU[4S4Y6TE2VTx?=	MnzHTY5pcWKrdHnvckBw\iCKRFHDNUBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiC5aYToJGlEPTBib3[gNk4zKM7:TR?=	NE\TT\|AzODR3MUO3PC=>
SCC4	MXrLbY5ie2ViQYPzZZk>	NFm5Zo0yKM7:TR?=	NXPaNG9NOjSq		NX7rblNIUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJR2[nWuaX6gZYNmfHmuYYTpc44>	NIKyOGYzODR3MkKyOS=>
SCC4	M2DHbWtqdmG\|ZTDBd5NigQ>?	M{fiNFEh\|ryP	NHvsOWIzPGh?		MULJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCjY3X0fYxifGmxbh?=	M4Xtc\|IxPDV{MkK1
SCC4	M{PxXWZ2dmO2aX;uJGF{e2G7	Mn;uNUDPxE1?	NVXuNGhXPSCvaX6=		NYq0NpdySWexbnnzeEBi[3Srdnn0fUBifCCYRGKgZZN{\XO\|ZXSgZZMhcW6mdXP0bY9vKG:oIFPZVFI1KGenbnWg[ZhxemW\|c3nvci=>	MVuyNFQ2OjJ{NR?=
NB4	MofnSpVv[3Srb36gRZN{[Xl?	MUK1JO69VQ>?	NGT5O5IzPCCq	MXvEUXNQ	NEe2fWxE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	NYO3NFN[OjB2OUG0OFA>
NB4	M1X6SmtqdmG\|ZTDBd5NigQ>?	NUHhR5NMPSEQvF2=	M3L3[VI1KGh?	NUSwcHROTE2VTx?=	M2X2N2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>?	MXGyNFQ6OTR2MB?=
NB4	NWP1cIRQTnWwY4Tpc44hSXO\|YYm=	MYm1JO69VQ>?	NYe4SZRbOjRiaB?=	M1n2NGROW09?	NYLhcG9UUW6mdXP0bY9vKG:oIICyNXdCTjFxQ1nQNUBmgHC{ZYPzbY9v	MlPFNlA1QTF2NEC=
NB4	MUDLbY5ie2ViQYPzZZk>	NVrPWoNQPSEQvF2=	M{fZR\|I1KGh?	MnTMSG1UVw>?	Mn;JTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgZYNmfHmuYYTpc44>	M2PxU\|IxPDlzNESw
NUGC3	NWT4fYtnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vZNWdKPTB;Mj65OEDPxE1?	NFLBZmYzODh3MEm3NS=>
A549	M16zdWZ2dmO2aX;uJGF{e2G7	NGrSXGM2KM7:TR?=	M3z5SlMhcA>?	NVX6V2dkTE2VTx?=	MYrJcoR2[3Srb36gc4Yh[XW2b4DoZYd6KGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hVEN\|SVm=	NV\OTnZHOjB6NUWyNFg>
HUT78	Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXy3NkBp	MWHEUXNQ	M4LGdWdKPTB;MD6zJO69VQ>?	NUjScJhVOjB6OESyNFg>
U937	M3rG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlzlO\|IhcA>?	M{XERmROW09?	NVvUeJdyT0l3ME2wMlM6KM7:TR?=	NWDtUnU5OjB6OESyNFg>
A431	NVrud4xjS3m2b4TvfIlkKEG\|c3H5		NV\nZmtFPzJiaB?=		NWLzelA5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA1NjJizszN	NHTOfWYzOTB6ME[yPS=>
A549	NGDGPJJEgXSxdH;4bYMhSXO\|YYm=		Moe5O\|IhcA>?		NUi2PW9PS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJTEGFIIfpeIghUUN3MDDv[kAyNjhizszN	MljoNlExQDB4Mkm=
CAL27	MXfDfZRwfG:6aXOgRZN{[Xl?		M3LFNlczKGh?		NX7aSlZmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=>	MlrpNlExQDB4Mkm=
HeLa	M{fZemN6fG:2b4jpZ{BCe3OjeR?=		NHLZcZo4OiCq		NEPXO25EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2=	NYjwb25SOjFyOEC2Nlk>
Sf21	M{XMPGtqdmG\|ZTDBd5NigQ>?		NILjbJk{KGh?		NIDMUWNKdmirYnn0bY9vKG:oIF\sZYchfGGpZ3XkJIh2dWGwIILlZ49u[mmwYX70JGhFSUN6IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS5{IN88US=>	M{jpT\|IyODhyNkK5
SKBR3	MXXDfZRwfG:6aXOgRZN{[Xl?		Moq5O\|IhcA>?		NXPkTZdWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uEUkOgZ4VtdHNib4\ldoV5eHKnc4PpcochUEWUMjD3bZRpKEmFNUCgc4YhOi54IN88US=>	NY[3NlBbOjFyOEC2Nlk>
SKOV3	M4\Ce2N6fG:2b4jpZ{BCe3OjeR?=		NEHLZng4OiCq		NV\nWXd1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNib4\ldoV5eHKnc4PpcochUEWUMjD3bZRpKEmFNUCgc4YhOi5{IN88US=>	NIHQWIMzOTB6ME[yPS=>
COR-L23	NHix[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33wXVExKM7:TR?=	NXrDSFJPPzJiaB?=	M3vuOGROW09?	MUXHTVUxRTFwMTFOwG0>	M3fHS\|IyODhyNkS3
DU145	M{HCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkWzNVAh\|ryP	NGjqXmE4OiCq	MlX2SG1UVw>?	MY\HTVUxRTFwMEWg{txO	MVGyNVA5ODZ2Nx?=
LoVo	M4LxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHrZpBpOTBizszN	MYW3NkBp	NH3JS3RFVVOR	MWHHTVUxRTFwNzFOwG0>	MUeyNVA5ODZ2Nx?=
MCR5-SV2	M2DSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3zU2FvOTBizszN	NHKweFk4OiCq	M4i3PGROW09?	NXvPWZVPT0l3ME2yMlEh\|ryP	NHP1VGYzOTB6ME[0Oy=>
HCT116	MoPnT4lv[XOnIFHzd4F6	MWmzNEDPxE1?	MmnmN\|AhcA>?	NHHRXItFVVOR	M{jIT2lvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIFteGijLYT1ZpVtcW5iYXPleJlt[XSrb36=	MVuyNVA5ODZ2Nx?=
HCT116	MYLLbY5ie2ViQYPzZZk>	Mn7LN\|Ah\|ryP	NVLHTWozOzBiaB?=	NHTSPWJFVVOR	NYPzfnNLUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	MnnGNlExQDB4NEe=
U937	MWrLbY5ie2ViQYPzZZk>	NV7Vcok5PSEQvF2=	Mo[4NlQhcA>?	M3ruVmROW09?	M{XGfGlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KEt7	NWXNb4hxOjF{OUK0PVI>
U937	M1LkfGtqdmG\|ZTDBd5NigQ>?	M17GU\|Uh\|ryP	MoLvNlQhcA>?	M2X5XmROW09?	NEm2RXZKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4Yh[WOndInsZZRqd25ib3[gbIl{fG:wZTDIN{BifCCNMUi=	NGDDcY0zOTJ7MkS5Ni=>
U937	Mny5T4lv[XOnIFHzd4F6	MnLJOUDPxE1?	MlK0NlQhcA>?	MnjOSG1UVw>?	MUfJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gdIFvNWGlZYT5cIF1\WRiaHnzeI9v\SCKNDDs[ZZmdA>?	M37xVlIyOjl{NEmy
U937	MnPVT4lv[XOnIFHzd4F6	M3zvXVUh\|ryP	MXGxOUBucW5?	NGjhcnFFVVOR	NFvEV4NKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjDs[ZZmdA>?	Ml3kNlEzQTJ2OUK=
A2780	M3nWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEH0NGE6PiCq	MX;EUXNQ	MlXzTWM2OD1zLk[yJO69VQ>?	NITPU2QzOTZ\|NESzNC=>
COLO205	NX\2Z2E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml;LPVYhcA>?	NVy1ZmlITE2VTx?=	M3jh[2lEPTB;Mj6xNkDPxE1?	NXXXOmZTOjF4M{S0N\|A>
Hep3B	MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnzuOFghcA>?	NUC4fHgzTE2VTx?=	NUWyXZh{T0l3ME2xMlIyKM7:TR?=	MlHxNlE4OTJzNE[=
GM11272	NXTiPFgzTnWwY4Tpc44hSXO\|YYm=	MVixNFAhdk1?	NULie4VQPzJiaB?=	NH;0XWxFVVOR	NEfrSWJT\WGldHn2ZZRqd25ib3[gUYVEeDJibYX0ZY51KGW6cILld5Nqd25iYYSgNVAhfG9iMUCwJI5O	NG\YNnczOTh2MEexOi=>
CFBE41o	MWjLbY5ie2ViQYPzZZk>	MoP5OUDPxE1?		MlzPSG1UVw>?	NVH0cIF[TG:5bjDy[Yd2dGG2aX;uJI9nKEiGQVO3JIF1KDBwMjD0c{A2KHWP	MW[yNVk5PDl3OB?=
CFBE41o	MUDGeY5kfGmxbjDBd5NigQ>?	M2PRc\|Eh\|ryP	Ml7qNlQhcA>?	M4jnNmROW09?	M33FeXJme3SxcnH0bY9vKG:oIFPGWHIh\GWudHHGOVA5KG23dHHueEB1emGoZnnjb4lv\yC2bzDj[YxtKHO3cn\hZ4Uh[XNiZ3z5Z49nd3Kvcx?=	M1v6blIyQTh2OUW4
DU145	MorKT4lv[XOnIFHzd4F6	NI\YVlQzNjVizszN	M{T0cFI1KGh?	MXHEUXNQ	MWLJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJJAzOXejZkGgdJJwfGWrbjDlfJBz\XO\|aX;u	M{HkeFIzOjZyMU[2
DU145	MlnnT4lv[XOnIFHzd4F6	NVHQNldbPSEQvF2=	NV65[\|ZZOjRiaB?=	NGnEZmtFVVOR	NImzNplKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\SCKNDDhZ4V1gWyjdHnvci=>	NGLHUVczOjJ4MEG2Oi=>
DU145	MV7LbY5ie2ViQYPzZZk>	M1\4VlUh\|ryP	MXiyOEBp	NEPSOVFFVVOR	MUfJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcGm\|dH;u[UBJOyCqeYDldoFk\XS7bHH0bY9v	MUOyNlI3ODF4Nh?=
786-0	NYTFSm9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXW2MlIh\|ryP	M{jUWFczKGh?	MXjEUXNQ	MYPHTVUxRTNwMjFOwG0>	M4PofFIzPDN3Nk[5
A498	MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUW2MlIh\|ryP	NEHXRpk4OiCq	MX;EUXNQ	M1fQeGdKPTB;MT62JO69VQ>?	NULic4ltOjJ2M{W2Olk>
A549/ATCC	NX\0fXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3m2T\|YvOiEQvF2=	NUXNS3Q6PzJiaB?=	Mnr3SG1UVw>?	NV;RSIZnT0l3ME2xMlYh\|ryP	MlTSNlI1OzV4Nkm=
ACHN	NUDabJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrHN\|hCPi5{IN88US=>	NWXYflltPzJiaB?=	NITCSJdFVVOR	NHrv[oNIUTVyPUGuN{DPxE1?	NH3VN2EzOjR\|NU[2PS=>
BT549	MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nZXVYvOiEQvF2=	MXq3NkBp	NWHz[nNITE2VTx?=	MnW3S2k2OD1zLkOg{txO	Mk\JNlI1OzV4Nkm=
EKVX	NIXMOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWi2MlIh\|ryP	NIHDNmU4OiCq	NVLScFY6TE2VTx?=	NH\OUY1IUTVyPUGuN{DPxE1?	NHfTNZUzOjR\|NU[2PS=>
HCT15	MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjvTHhWPi5{IN88US=>	M2q2OlczKGh?	NWjHb5BjTE2VTx?=	NHrhXnBIUTVyPUKuOUDPxE1?	MXKyNlQ{PTZ4OR?=
HOP92	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\qRpFOPi5{IN88US=>	M3PFRlczKGh?	MlPOSG1UVw>?	M2\JNGdKPTB;NDFOwG0>	NUe1XFRsOjJ2M{W2Olk>
IGROV1	M33vVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUC2MlIh\|ryP	MlO0O\|IhcA>?	M17kdmROW09?	MYLHTVUxRTFwMzFOwG0>	NH\5SXUzOjR\|NU[2PS=>
LOXIMVI	NGPBWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWm2MlIh\|ryP	M{\tNVczKGh?	MX;EUXNQ	M1nXWGdKPTB;MTFOwG0>	MnXaNlI1OzV4Nkm=
M14	Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXLOk4zKM7:TR?=	M3LrZ\|czKGh?	NXS3VolvTE2VTx?=	MkLoS2k2OD1zLkOg{txO	M2nhT\|IzPDN3Nk[5
MALME-3M	NHS2PZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEW0dHg3NjJizszN	M{Ht[VczKGh?	MnfuSG1UVw>?	M{XIXmdKPTB;MD6zNkDPxE1?	NXPZUWZXOjJ2M{W2Olk>
MCF10A	M3X5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jkbFYvOiEQvF2=	NX3YRpAzPDhiaB?=	MY\EUXNQ	MWrHTVUxRTlwNjFOwG0>	Mlz3NlI1OzV4Nkm=
MDA-MB-435	NV\2SVdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTMU4I3NjJizszN	MmDmO\|IhcA>?	MojaSG1UVw>?	NYq2eoN{T0l3ME2wMlUh\|ryP	M{HSbVIzPDN3Nk[5
MDA-MB-468	NEC4RmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{S2bVYvOiEQvF2=	MmrjO\|IhcA>?	NX\0TFBTTE2VTx?=	M2rpS2dKPTB;MD62N{DPxE1?	MX6yNlQ{PTZ4OR?=
MOLT4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLaXFdpPi5{IN88US=>	NF33bmc4OiCq	NEPlTYlFVVOR	M4r0RWdKPTB;MD60JO69VQ>?	NIf4[GYzOjR\|NU[2PS=>
NCI-ADR-RES	MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnlTFdjPi5{IN88US=>	MWq3NkBp	MliwSG1UVw>?	MoDRS2k2OD1yLkG2JO69VQ>?	MkP2NlI1OzV4Nkm=
NCI-H23	NFTXOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoW2Ok4zKM7:TR?=	NUi2Rok2PzJiaB?=	NYPZWldvTE2VTx?=	NF7LVoZIUTVyPUGg{txO	MnfVNlI1OzV4Nkm=
NCI-H322M	M{i4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHmOk4zKM7:TR?=	M3;lblczKGh?	MnTGSG1UVw>?	Ml3CS2k2OD1yLke5JO69VQ>?	NVvPc\|hiOjJ2M{W2Olk>
NCI-H460	NILFPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\ROFYvOiEQvF2=	M3T1O\|czKGh?	MUnEUXNQ	NXPOWnNGT0l3ME2wMlc6KM7:TR?=	NFqxbmgzOjR\|NU[2PS=>
NCI-H522	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjHOk4zKM7:TR?=	NIToXYQ4OiCq	NXOyVXNFTE2VTx?=	M{HaOWdKPTB;MD61JO69VQ>?	M1v1UVIzPDN3Nk[5
OVCAR3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXuTVJpPi5{IN88US=>	NGTTW2o4OiCq	MV;EUXNQ	NH2we4tIUTVyPUGuN{DPxE1?	M{XIZ\|IzPDN3Nk[5
OVCAR4	MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\FTnU1Pi5{IN88US=>	NHPM[484OiCq	NWjqc3FITE2VTx?=	MXHHTVUxRTRizszN	NGCzWIUzOjR\|NU[2PS=>
OVCAR5	NH3PV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoL0Ok4zKM7:TR?=	MmLpO\|IhcA>?	NY\COYY1TE2VTx?=	M1jsdGdKPTB;MD63PUDPxE1?	MXWyNlQ{PTZ4OR?=
OVCAR8	M2\1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:2MlIh\|ryP	M323NlczKGh?	MlS4SG1UVw>?	MkfRS2k2OD1yLkWg{txO	MnqxNlI1OzV4Nkm=
RXF393	MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnn6Ok4zKM7:TR?=	MUC3NkBp	NHi5fGVFVVOR	MWTHTVUxRTFwMzFOwG0>	NE\vPIwzOjR\|NU[2PS=>
SF268	NWjOOnZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\QbWZ{Pi5{IN88US=>	NUf4PJk6PzJiaB?=	M3\2OWROW09?	MknuS2k2OD1zLk[g{txO	MViyNlQ{PTZ4OR?=
SF295	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f1SlYvOiEQvF2=	NESydZE4OiCq	MmXKSG1UVw>?	NVfrdIdxT0l3ME2xMlYh\|ryP	M2\kXlIzPDN3Nk[5
SF539	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV62MlIh\|ryP	M1PmfVczKGh?	MWDEUXNQ	NVmxUYhoT0l3ME2yJO69VQ>?	NIPBO3UzOjR\|NU[2PS=>
SK-MEL-2	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\6Ok4zKM7:TR?=	MVS3NkBp	M3zseWROW09?	NVO0TFhmT0l3ME2xMlMh\|ryP	NYLPW2t{OjJ2M{W2Olk>
SK-MEL-28	M{jqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvESXF4Pi5{IN88US=>	MlLlO\|IhcA>?	NHu1TFRFVVOR	NH3MbpNIUTVyPUGg{txO	MkizNlI1OzV4Nkm=
SK-MEL-5	NIjzc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XsXFYvOiEQvF2=	MXu3NkBp	M3vucGROW09?	NV3sfGM{T0l3ME2wMlY{KM7:TR?=	M3TkbFIzPDN3Nk[5
SKOV3	NF;NXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVe2MlIh\|ryP	NIThPYw4OiCq	NILrXo1FVVOR	M2PvdmdKPTB;MTFOwG0>	M1PBeFIzPDN3Nk[5
SN12C	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXrOk4zKM7:TR?=	MorUO\|IhcA>?	MlPySG1UVw>?	NIr5V4dIUTVyPUKg{txO	NH3aboEzOjR\|NU[2PS=>
SNB19	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHmOk4zKM7:TR?=	NWPyR5c2PzJiaB?=	NV7iOI5uTE2VTx?=	NUjoUItsT0l3ME2wMlY{KM7:TR?=	M1zyWFIzPDN3Nk[5
SNB75	NILyc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT0S2VwPi5{IN88US=>	MVS3NkBp	NXzIN\|E3TE2VTx?=	NFLqeXVIUTVyPUCuO\|kh\|ryP	MlG3NlI1OzV4Nkm=
SR	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfIOk4zKM7:TR?=	MXi3NkBp	MoXRSG1UVw>?	MV7HTVUxRTBwNDFOwG0>	MnGxNlI1OzV4Nkm=
T47D	NFLDfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rGeVYvOiEQvF2=	NFnrdHM4OiCq	MlLESG1UVw>?	NW\uUppET0l3ME2wMlUh\|ryP	NHfYbFAzOjR\|NU[2PS=>
TK10	M{nOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX22MlIh\|ryP	MXq3NkBp	MVXEUXNQ	MorMS2k2OD1yLk[zJO69VQ>?	NGW5dZQzOjR\|NU[2PS=>
UACC257	NFnUepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnL6Ok4zKM7:TR?=	MV:3NkBp	MoTzSG1UVw>?	NUmzOJJmT0l3ME2wMlUh\|ryP	NX\NdYpqOjJ2M{W2Olk>
UACC62	NYnDNGgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvKUJI3NjJizszN	NV;Yc2VUPzJiaB?=	NVTCeIN{TE2VTx?=	NUXCSWI1T0l3ME2wMlQh\|ryP	M4DVV\|IzPDN3Nk[5
UO31	NVHwWllqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj3Ok4zKM7:TR?=	M1XzS\|czKGh?	MlzOSG1UVw>?	NFXpOGNIUTVyPUCuOUDPxE1?	Mnn5NlI1OzV4Nkm=
Hep3B	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWLvRnpPPDhiaB?=	M1HpUGROW09?	NH[4[VJIUTVyPUCuOlkh\|ryP	NX3PUWtbOjJ2M{m4OlM>
BE(2)-C	NEm3VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoLFO\|IhcA>?	NULY[25VTE2VTx?=	MXvJR\|cxRTJizszN	MoLiNlI6OzJ\|MU[=
Bel7402	NFXwPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXjtWJloPzJiaB?=	M1PtSWROW09?	NUC0Um1kT0l7ME2xO{DPxE1?	NWLWVnd{OjNyNkGzO\|Y>
Bel7404	MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFTuXII4OiCq	M4\ydGROW09?	MVjHTVkxRTF6IN88US=>	NYjNeYo6OjNyNkGzO\|Y>
BGC823	M4e5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3y5eVczKGh?	MUjEUXNQ	MULHTVkxRTdwNTFOwG0>	NILoOnczOzB4MUO3Oi=>
MGC803	NFfkWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYW3NkBp	MVfEUXNQ	NX\W[JNxT0l7ME2xNE45KM7:TR?=	NXzKTnRuOjNyNkGzO\|Y>
SGC7901	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXLvNGR4PzJiaB?=	NH7jN2xFVVOR	NIPyZ5FIUTlyPUmuOEDPxE1?	NEXKO3UzOzB4MUO3Oi=>
SKHEP1	NUTQWoRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV[3NkBp	NIPnSohFVVOR	M1nUV2dKQTB;MUeg{txO	NVrqSpRGOjNyNkGzO\|Y>
SMMC7721	M4XNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPpcm44PzJiaB?=	NGPqc5pFVVOR	MlzIS2k6OD1{MDFOwG0>	NWTSd2tJOjNyNkGzO\|Y>
NUGC3	M4Pa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUW5d\|hkOTBizszN			M{exeGdKRTJwOUSg{txO	NXv4WJFGOjNzNkOzN\|I>
A2780 CisR	MXHLbY5ie2ViQYPzZZk>		MlnSNVghcA>?		NWjmPI91UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlQ1KM7:TR?=	MUKyN\|I2OjZyMx?=
CAL27 sens	MYPLbY5ie2ViQYPzZZk>		NF65dFIyQCCq		MmXkTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkO2JO69VQ>?	MV2yN\|I2OjZyMx?=
CAL27 CisR	NG[5WZdMcW6jc3WgRZN{[Xl?		MljJNVghcA>?		M3P0TmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	MWqyN\|I2OjZyMx?=
KYSE-510 CisR	MnLpT4lv[XOnIFHzd4F6		MX[xPEBp		M2LwWWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61PUDPxE1?	MmK2NlMzPTJ4MEO=
KYSE-510 sens	MXvLbY5ie2ViQYPzZZk>		MV[xPEBp		MoX3TY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkeg{txO	MWSyN\|I2OjZyMx?=
MDA-MB-231 sens	NUfZVmJzU2mwYYPlJGF{e2G7		MlS0NVghcA>?		M3PTS2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	NWW4RoloOjN{NUK2NFM>
MDA-MB-231 CisR	M{XUWmtqdmG\|ZTDBd5NigQ>?		NV3ISWVDOThiaB?=		MVjJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	MlnoNlMzPTJ4MEO=
ES2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVTtemNOPDhiaB?=	M3jneWROW09?	NUPuXnJiUUN3ME2xNk44KM7:TR?=	MWeyN\|Q6OzR2OR?=
MDA-MB-231	MkjCT4lv[XOnIFHzd4F6	M4m4TVExKM7:TR?=	MV2zNEBucW5?	NGjJTmNFVVOR	MVPJcohq[mm2aX;uJI9nKEiGQVOyZS=>	MX6yN\|Q6OzR2OR?=
MDA-MB-231	Ml;iT4lv[XOnIFHzd4F6	MYixJO69VQ>?	NFLPdmMzPCCq	MWnEUXNQ	M3rGOWlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXPleJlt[XSrb36gcIV3\Wy\|IH;mJJR2[nWuaX6=	MX2yN\|Q6OzR2OR?=
HS68	NWXaSIE5S3m2b4TvfIlkKEG\|c3H5	MlPTNVAh\|ryP	MlLjO\|IhcA>?	MkS0SG1UVw>?	NVHUZ2VLUUN3ME20MlYh\|ryP	NW\LN4t4OjN3N{C1OFI>
MEF	M3zJfGN6fG:2b4jpZ{BCe3OjeR?=	MX:xNEDPxE1?	M3L3ZlczKGh?	MVTEUXNQ	M2niXGlEPTB;ND60JO69VQ>?	NEHjZ5YzOzV5MEW0Ni=>
BGC823	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFHad49FVVOR	NHTVR5lIUTVyPUOuNFkh\|ryP	MlW0NlM3ODF5ME[=
High5	M4rCWWtqdmG\|ZTDBd5NigQ>?		M{jyTFI1KGh?		MnjETY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOkB4cXSqIFnDOVAhd2ZiMD6wPUDPxE1?	M2LBelI{PjB{NUKz
High5	MYXLbY5ie2ViQYPzZZk>		MWOyOEBp		NY\wV5pmUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOSC5aYToJGlEPTBib3[gNE4yOiEQvF2=	NEDDVWwzOzZyMkWyNy=>
High5	MnPYT4lv[XOnIFHzd4F6		MWSyOEBp		MmDOTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDN{B4cXSqIFnDOVAhd2ZiMD6xO{DPxE1?	NGH2TmgzOzZyMkWyNy=>
A549	M{LOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVLEUXNQ	M1jN[2lEPTB;MT6wO\|kh\|ryP	MnvDNlM3PDR{MUC=
HCT116	NF6xU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUfWepl5TE2VTx?=	MkXXTWM2OD1yLke1O{DPxE1?	NFi3NWczOzZ2NEKxNC=>
K562	M2TleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3PtcmROW09?	NH3DSndKSzVyPUCuOlQ2KM7:TR?=	MV6yN\|Y1PDJzMB?=
GBC-SD	M1rPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY[1JO69VQ>?	Mn3TO\|IhcA>?	M{TvVGROW09?	NH;5fFZKSzVyPUG0Mlgh\|ryP	MU[yN\|cxPzJ4MB?=
HGC27	M3\SdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mki5OUDPxE1?	MXO3NkBp	MlvlSG1UVw>?	NVPzZlVTUUN3ME21MlQh\|ryP	MoPZNlM4ODd{NkC=
HL60	M3XtOWtqdmG\|ZTDBd5NigQ>?	NIfKUnc2KM7:TR?=	MlnpNlQhcA>?	M{DY[WROW09?	NEHZT3JKdmirYnn0bY9vKG:oIFjERWM>	NF7a[mEzOzdyN{K2NC=>
Vero	M4K0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MonnO\|IhcA>?	MXPEUXNQ	MYTJR\|UxRTBwOTFOwG0>	NVL4Z5NWOjN5OE[0OVI>
NCI60	MXfDfZRwfG:6aXOgRZN{[Xl?		M{mycVQ5KGh?	MWfEUXNQ	Moe0S2k:OC53MzFOwG0>	MWmyOFAyPTN{Nx?=
SW620	NGewdFlEgXSxdH;4bYMhSXO\|YYm=		NV;US\|FOPDhiaB?=	NVPEZ5c{TE2VTx?=	NF7xbphIUT1yLkW0JO69VQ>?	NGfhW4wzPDBzNUOyOy=>
U251	M3;mZWN6fG:2b4jpZ{BCe3OjeR?=		NHKwdI01QCCq	M1Lz[GROW09?	MmnLS2k:OS53MzFOwG0>	MVSyOFAyPTN{Nx?=
KM12	NHq5bpZEgXSxdH;4bYMhSXO\|YYm=		M1XHN\|Q5KGh?	NIPHOFBFVVOR	MlnsS2k:OS56ODFOwG0>	NWjnZ5FCOjRyMUWzNlc>
Hs578T	NULWbZo4S3m2b4TvfIlkKEG\|c3H5		MmXMOFghcA>?	NUfsTGVJTE2VTx?=	M{i3fGdKRTRwOEOg{txO	M2rqb\|I1ODF3M{K3
MDA-MB-231	NYPGN25KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4S2XVQ5KGh?		NV7I[2d7UUN3ME2wMlE3KM7:TR?=	NV70PFJPOjRyOUWwNVY>
MCF7	NHPiV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGnJRmo1QCCq		NFPsSFBIUT1yLkS1JO69VQ>?	MV[yOFEyQTV3NR?=
MDA-MB-435	NXfXNGFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MknvOFghcA>?		NU\ZeZZ6T0l;MD64PEDPxE1?	M1nHbVI1OTF7NUW1
AsPC1	M17Ebmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1u2TlMxKM7:TR?=	M2m1UVQ5KGh?	MkXUSG1UVw>?	M{fIW2lEPTB;Mz62OkDPxE1?	MlXoNlQyQDV\|N{i=
Jurkat E6.1	NHvNdpdMcW6jc3WgRZN{[Xl?		NFfhVpYzKGh?	MoPWSG1UVw>?	NIroNG1KdmirYnn0bY9vKG:oIFjERWM1KHerdHigTWM2OCCxZjCwMlA1KM7:TR?=	MVmyOFI3OTh4Mh?=
KG1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2XqXVQ5KGh?		MVXJR\|UxRTFwMUWg{txO	M3;ib\|I1PTJ3MECz
HEL	NV33WmRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTOOFghcA>?	MorCSG1UVw>?	NUjp[o1jUUN3ME2wMlQ6KM7:TR?=	MnvxNlQ3QTRyNUW=
HSC3	NXr1N41XS3m2b4TvfIlkKEG\|c3H5		M3rtUVEzKGh?	MlrsSG1UVw>?	MoLHTWM2OD1yLkexJO69VQ>?	M4nEPFI1PzZ4NU[w
HT-29	MXzDfZRwfG:6aXOgRZN{[Xl?		MUmxNkBp	MkDWSG1UVw>?	MYLJR\|UxRTBwN{Kg{txO	MYeyOFc3PjV4MB?=
KB	M{LCWWN6fG:2b4jpZ{BCe3OjeR?=		NEnFXoYyOiCq	M33sb2ROW09?	NETIWZZKSzVyPUCuO\|Uh\|ryP	M{nhR\|I1PzZ4NU[w
H460	NY\3[25YS3m2b4TvfIlkKEG\|c3H5		M332[lEzKGh?	NF3qRWVFVVOR	M32ySmlEPTB;MD64NkDPxE1?	MUOyOFc3PjV4MB?=
MONE1	M2qxc2N6fG:2b4jpZ{BCe3OjeR?=		NIXLWmQyOiCq	NGLnVW9FVVOR	NGXnRnJKSzVyPUGuNVgh\|ryP	MWWyOFc3PjV4MB?=
MKN45	MUTDfZRwfG:6aXOgRZN{[Xl?		NIW5V2gyOiCq	Mme1SG1UVw>?	M{m4WGlEPTB;MT6yOUDPxE1?	NIXDOW0zPDd4NkW2NC=>
TSGH	M37NdmN6fG:2b4jpZ{BCe3OjeR?=		M1;wdVEzKGh?	NIHk[oFFVVOR	MlzCTWM2OD1{LkC5JO69VQ>?	MXyyOFc3PjV4MB?=
HL60	NVnQPG5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MW[3NkBp	MmWzSG1UVw>?	MmnCS2k2OD1yLkmzJO69VQ>?	M1uzblI1QTByNUCw
HEK293	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWq3NkBp	NYj1UVJOTE2VTx?=	NHnFZ2ZIUTVyPUGzJO69VQ>?	MUGyOFkxODVyMB?=
Jurkat	NXG2V3BiS3m2b4TvfIlkKEG\|c3H5	NID0WoUyODBizszN	M3y1[\|czKGh?		MYLHTVUxRTBwOTFOwG0>	MWGyOFkxODd2Mx?=
GM15850	Ml;iT4lv[XOnIFHzd4F6	MWKyMlUh\|ryP	NVHpdnp7QTZiaB?=	M1m3W2ROW09?	MkLM[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MX6xOlkzOTN4Nx?=
GM15850	NVPNdIxnU2mwYYPlJGF{e2G7	M{niR\|IvPSEQvF2=	MlH4PVYhcA>?	MXTEUXNQ	MWPkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NYfrWoZiOTZ7MkGzOlc>
GM15850	MV;LbY5ie2ViQYPzZZk>	MX:yMlUh\|ryP	MoDGPVYhcA>?	NVr2cY5JTE2VTx?=	NHXiXphld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTJiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NWjRVXFIOTZ7MkGzOlc>
GM15850	NHTNOoRMcW6jc3WgRZN{[Xl?	MVOyMlUh\|ryP	NYHkfndkQTZiaB?=	Mo\5SG1UVw>?	MknV[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MnPsNVY6OjF\|Nke=
GM15850	NGK0PVdMcW6jc3WgRZN{[Xl?	NVTOZYQ4Oi53IN88US=>	NW\XdGJZQTZiaB?=	MWnEUXNQ	MVHkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgPEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NWfhUJI2OTZ7MkGzOlc>
GM15850	M2frWmtqdmG\|ZTDBd5NigQ>?	NXvqVHJQOi53IN88US=>	M2fj[Fk3KGh?	MmrYSG1UVw>?	NInm[oVld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTZiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NYnOSGt{OTZ7MkGzOlc>
GM15850	MYjGeY5kfGmxbjDBd5NigQ>?	NV7r[3l3PSEQvF2=	NEHtSWQyOiCq	NFzDV25FVVOR	MnHKbIF{KG6xIHXm[oVkfCCxbjDGXG4hdVKQQTDlfJBz\XO\|aX;u	NUPHZm41OTZ7MkGzOlc>
U937	NVPtOpJPU2mwYYPlJGF{e2G7	MXS1JO69VQ>?	MmW3NlQhcA>?	NHzPXIJFVVOR	NVOyV3ZycGG\|IH7vJIVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u	M1jzV\|E4PDR5N{Ww
U937	NILYeGJMcW6jc3WgRZN{[Xl?	NFLCRlIyKM7:TR?=	MmDiNlQhcA>?	NWrVZmJmTE2VTx?=	MmXhbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	NIDCb3IyPzR2N{e1NC=>
PANC1	M1fObWZ2dmO2aX;uJGF{e2G7	MXGxJO69VQ>?	MoPMNlQhcA>?		MXPkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	M3q2eVE4PTh6N{S0
PANC1	NHvDVVJHfW6ldHnvckBCe3OjeR?=	NYrVOXNxOSEQvF2=	MUi0PEAhcA>?		MVvkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	NWD1N2M1OTd3OEi3OFQ>
Caco-2	NHPKTodHfW6ldHnvckBCe3OjeR?=	M37KO\|Uh\|ryP	NW\nTWxUOjRiaB?=	NYLMeXRXTE2VTx?=	M4LLVYRw\XNibn;0JIlv\HWlZTDQNlFYSUZzIHflcoUh\XiycnXzd4lwdg>?	NFq1W5IzODF2M{i0NC=>
SCC4	NEXF[4tHfW6ldHnvckBCe3OjeR?=	MkL1NUDPxE1?	MoX5NVAhdWmw	MXTEUXNQ	MoGwbIF{KG6xIHHnc45qe3RiYXP0bZZqfHliYYSgWmRTKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBEYVB{NDDn[Y5mKGW6cILld5Nqd25?	NVn0N\|hCOjB2NUKyNlU>
A549	NWrIdmtHTnWwY4Tpc44hSXO\|YYm=	MYe1JO69VQ>?	MW[zJIg>	MkL3SG1UVw>?	MVnkc4V{KG6xdDDpcoR2[2ViYYX0c5Bp[We7IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ	M4\KXlIxQDV3MkC4
HCT116	M1fxV2tqdmG\|ZTDBd5NigQ>?	NXfFbIxtOC5\|IN88US=>	MnG4N\|AhcA>?	MVfEUXNQ	NGnFXY9ld2W\|IH7veEBqdmirYnn0JGhFSUNzIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCqaYP0c45mKEh\|S{mgZYNmfHmuYYTpc44>	M2\qPFIyODhyNkS3
HepG2	NGHOb5VHfW6ldHnvckBCe3OjeR?=	NEHQbG0yOCEQvF2=	M1K2WlI1KGh?	MnjVSG1UVw>?	NWHWPGw1\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCqeYDldoFk\XS7bHH0bY9vKG:oIIC1Ny=>	Mne5NlE2PDh3OEK=
GM11272	NGLRZWRHfW6ldHnvckBCe3OjeR?=	NInrPJYxNjFizszN	M2e1RlczKGh?	M3HsWGROW09?	NYLhSFh[\G:nczDuc5QhemWjY4TpeoF1\SCPZVPwNkBufXSjboSg[ZhxemW\|c3nvci=>	MljqNlE5PDB5MU[=
MDA-MB-231	Mo[zT4lv[XOnIFHzd4F6	MVmxNEDPxE1?	Mlz2OUBucW5?	NUnuTWh1TE2VTx?=	M3PVNIRw\XNibn;0JIlvcGmkaYSgTGRCSzKj	NVfLNHVyOjN2OUO0OFk>
MDA-MB-231	NE\XV4JMcW6jc3WgRZN{[Xl?	NUK5XYNxOSEQvF2=	NYfPSW1xOjRiaB?=	M{LxdWROW09?	MV3kc4V{KG6xdDDpcohq[mm2IFjERWM3KGG\|c3Xzd4VlKGG\|IHHj[ZR6dGG2aX;uJIxmfmWuczDv[kB1fWK3bHnu	NXvuRpplOjN2OUO0OFk>
K562	M1HCVmtqdmG\|ZTDBd5NigQ>?				M1vzTIRw\XNibn;0JIlvcGmkaYSgTGRCSw>?	MUWyN\|U6OTFzMR?=
Jurkat	NIXZe5hEgXSxdH;4bYMhSXO\|YYm=	M2KwU\|IxKM7:TR?=	NFXKW4Y4OiCq	NUizenZlTE2VTx?=	NEDtWVFvdyCleYTveI95cWOrdImgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44>	NYjLTFl1OjR\|MESzOFg>
HCT116	M2rM[GFxd3C2b4Ppd{BCe3OjeR?=	NXT4SGVbOyEQvF2=	M4niW\|I1KGh?	NEnaO5pFVVOR	MVXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKHB3MzDwdo91\WmwIHzleoVt	M4fxOlI1PzZ4NU[w
KASUMI-1	M3fwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PoW2lEPTB;OUmuNVchdk1?	MUjTRW5ITVJ?
KARPAS-45	M{\hVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\Xd4lKSzVyPUG3N{45QSCwTR?=	M3vNfXNCVkeHUh?=
BHT-101	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLiTWM2OD1{NESuNVghdk1?	NYLCNndmW0GQR1XS
H9	NWDJO\|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXpdmlWUUN3ME2yOVUvODRibl2=	MkLaV2FPT0WU
PA-1	Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoO0TWM2OD1{OE[uNlYhdk1?	Ml72V2FPT0WU
NEC8	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M333WmlEPTB;Mki5MlM5KG6P	M1rtdXNCVkeHUh?=
MHH-PREB-1	NIfLTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfVTZlKSzVyPUK5OE42OyCwTR?=	MYPTRW5ITVJ?
NB7	NWjtW4pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTN2NT63OEBvVQ>?	NUnyUHBSW0GQR1XS
A3-KAW	NWq5NVVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTRyMD61PUBvVQ>?	Mny2V2FPT0WU
NB69	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVq5NIIxUUN3ME20NVEvPzFibl2=	NYPJSWhZW0GQR1XS
EoL-1-cell	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXrTWM2OD12NUSyOUBvVQ>?	M1r0[nNCVkeHUh?=
CHP-212	MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTwcXhKSzVyPUS1O{42OyCwTR?=	MUfTRW5ITVJ?
C2BBe1	NVrnO25FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fuZmlEPTB;NEeyMlE6KG6P	Mm\1V2FPT0WU
697	NFrVUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTR5Mz60NUBvVQ>?	M1XNO3NCVkeHUh?=
BCPAP	NEnBR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYn1OHN{UUN3ME21NFEvPDJibl2=	NEXK[YJUSU6JRWK=
L-363	NYi4eHB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELFcG1KSzVyPUWwN{4yKG6P	NUXIVmFrW0GQR1XS
ES8	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTUWINlUUN3ME21NlMvPTNibl2=	MlrYV2FPT0WU
BE-13	NYTOcZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPMTWM2OD13Mk[uPVYhdk1?	NXi4[lNDW0GQR1XS
CTB-1	M{fqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTV\|Nz65NkBvVQ>?	MlXsV2FPT0WU
HD-MY-Z	Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\jdGZKSzVyPUWzPE4yOyCwTR?=	NHH4SG9USU6JRWK=
NKM-1	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGq0dIZKSzVyPUW0OE4zPyCwTR?=	MnvRV2FPT0WU
NCI-H720	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzJUlNzUUN3ME21OlAvOThibl2=	M360XHNCVkeHUh?=
KY821	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVWydnRTUUN3ME21OlMvOjVibl2=	MlTwV2FPT0WU
OVCAR-5	MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTV5Nj6xNUBvVQ>?	M1L3bXNCVkeHUh?=
CTV-1	NX7SWIoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTV6MT61OkBvVQ>?	MX\TRW5ITVJ?
P12-ICHIKAWA	M4fw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTV7Nj61NUBvVQ>?	MWPTRW5ITVJ?
DB	M3LYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXPTWM2OD13OUiuOVchdk1?	NHHwUpZUSU6JRWK=
CHL-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XxXGlEPTB;NkSyMlA5KG6P	NVjxenNkW0GQR1XS
A4-Fuk	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTDVmNTUUN3ME22OFQvQTFibl2=	MnH0V2FPT0WU
MV-4-11	M1LHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnMbmVKSzVyPU[1PU4yKG6P	MmjLV2FPT0WU
RPMI-8226	M4rWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HJSmlEPTB;Nke4MlE5KG6P	NGfZUGRUSU6JRWK=
NB14	M3;t[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrqTWM2OD14OU[uPVUhdk1?	MnfvV2FPT0WU
DOHH-2	NYDNXpY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXHd2NWUUN3ME23NFYvPjhibl2=	NEnZNpZUSU6JRWK=
D-423MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT4TWM2OD15ME[uPFkhdk1?	NHjZOIZUSU6JRWK=
D-283MED	NXXEUVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmL2TWM2OD15MUSuNVQhdk1?	Mo\HV2FPT0WU
ES1	NXjZNZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUSz[4ZVUUN3ME23NlQvPCCwTR?=	M2PyWnNCVkeHUh?=
GOTO	NVXqbY9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzsTWM2OD15MkmuNVIhdk1?	NEW1NZpUSU6JRWK=
NCI-H209	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XERWlEPTB;N{K5Mlkhdk1?	M{\uSXNCVkeHUh?=
MOLT-13	NXfldY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;ZS4p7UUN3ME23N\|gvQThibl2=	MUnTRW5ITVJ?
ATN-1	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTd2MD6yPEBvVQ>?	MoPwV2FPT0WU
DU-4475	M1rvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\yTWM2OD15NUGuPVEhdk1?	Ml3hV2FPT0WU
NB10	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;MTWM2OD15NUGuPVIhdk1?	M4LVZnNCVkeHUh?=
KG-1	NX;1e\|VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjLTWM2OD15N{WuOFUhdk1?	NH;hdmpUSU6JRWK=
MOLT-4	NWT0UZU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPFXI5KSzVyPUe4O{41PiCwTR?=	NXHrRVRYW0GQR1XS
TE-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HVS2lEPTB;N{mxMlEhdk1?	MlfBV2FPT0WU
SBC-1	Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPVTWM2OD15OUOuPFQhdk1?	MmOzV2FPT0WU
HEL	M1PQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfzWWZxUUN3ME24NFYvODhibl2=	NWrFcpVnW0GQR1XS
SK-MEL-2	NGqxR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTOWlZsUUN3ME24NFkvPDRibl2=	MYLTRW5ITVJ?
KU812	MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HacmlEPTB;OEGzMlEhdk1?	MU\TRW5ITVJ?
RPMI-8866	M4TCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\PVGlEPTB;OEGzMlY4KG6P	MV3TRW5ITVJ?
ALL-PO	M2D2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIX4WGtKSzVyPUixOE43PiCwTR?=	M4ntSHNCVkeHUh?=
LU-139	NF\pTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmj2TWM2OD16MkKuPFYhdk1?	NYrpU5Y2W0GQR1XS
RS4-11	NVnhSWFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fPbWlEPTB;OEOyMlQ2KG6P	MmjFV2FPT0WU
EW-18	NHXC[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\oemlEPTB;OEOyMlk3KG6P	MXXTRW5ITVJ?
P30-OHK	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTh\|NT63JI5O	Mm[wV2FPT0WU
D-566MG	M1XaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PGW2lEPTB;OEO4MlYzKG6P	NWXBdnRZW0GQR1XS
HSC-4	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4L2T2lEPTB;OES2MlUyKG6P	M2XxZXNCVkeHUh?=
QIMR-WIL	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4m3[2lEPTB;OE[yMlA{KG6P	M3HmVXNCVkeHUh?=
SW954	NFHYcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITQS\|VKSzVyPUi2N{4yPiCwTR?=	MnnJV2FPT0WU
HGC-27	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonxTWM2OD16N{KuN\|Qhdk1?	NYPKeZFZW0GQR1XS
HH	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HHcmlEPTB;OEm0MlEzKG6P	NHv3SJpUSU6JRWK=
KE-37	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfzTWM2OD16OUSuOlIhdk1?	MnL2V2FPT0WU
SK-N-DZ	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGq0XYxKSzVyPUmwNE41OyCwTR?=	MX7TRW5ITVJ?
J-RT3-T3-5	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\nTWM2OD17MUCuOFkhdk1?	Mmn0V2FPT0WU
A427	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPUSXlKSzVyPUmyNE45PCCwTR?=	M1j3cHNCVkeHUh?=
ECC10	NYTI[3BNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\lNmlEPTB;OUS1Mlg4KG6P	MmfuV2FPT0WU
EW-1	MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1r5S2lEPTB;OUS3MlI3KG6P	MXTTRW5ITVJ?
MIA-PaCa-2	M2H2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P5cWlEPTB;OUS5MlEzKG6P	MmPDV2FPT0WU
HCC2218	M4juVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nxTmlEPTB;OUW4MlQ5KG6P	Mlj1V2FPT0WU
HAL-01	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjjNmNKSzVyPUm2PE4xPCCwTR?=	NFTTUlZUSU6JRWK=
RD	M1rKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2S5XWlEPTB;OUe0MlQ2KG6P	NH3kV2FUSU6JRWK=
SK-N-AS	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXizS2pNUUN3ME25PFgvOSCwTR?=	NUnnS5dUW0GQR1XS
ML-2	M3[2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGr2O4lKSzVyPUGuNFA1ODdizszN	Ml\GV2FPT0WU
MEL-HO	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvIfIdUUUN3ME2xMlAxPTh{IN88US=>	MmPXV2FPT0WU
MS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDqTWM2OD1zLkCwOlE4KM7:TR?=	NYHVboZ7W0GQR1XS
NCI-SNU-1	NV;3[2dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkP0TWM2OD1zLkCyN\|MyKM7:TR?=	NIToeJBUSU6JRWK=
8505C	MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jwN2lEPTB;MT6wNlM{OSEQvF2=	M4HqRXNCVkeHUh?=
MN-60	M1zodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFwMEK2PEDPxE1?	NU\mTWlzW0GQR1XS
SAS	NHLsXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHHc5BKSzVyPUGuNFQxQDFizszN	NWXtRo1GW0GQR1XS
EFM-19	NFq4RZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUj6ZZhmUUN3ME2xMlA1QDd7IN88US=>	MnT6V2FPT0WU
Ca9-22	M33TZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vXXWlEPTB;MT6wOVExPyEQvF2=	MYHTRW5ITVJ?
NBsusSR	NWrqXWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{ixNmlEPTB;MT6wOVE3PiEQvF2=	MlrJV2FPT0WU
NB13	NYSybJNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHKTWM2OD1zLkC1OVAyKM7:TR?=	MVzTRW5ITVJ?
SF295	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfndI95UUN3ME2xMlA3PjJ2IN88US=>	NXO1d2o6W0GQR1XS
U-2-OS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfLTWM2OD1zLkC3PVEyKM7:TR?=	MXzTRW5ITVJ?
NCI-H526	NYWwUXBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTFwMEiyPVEh\|ryP	M4rFXXNCVkeHUh?=
KMOE-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFwMEm0NlIh\|ryP	NX3zT3oxW0GQR1XS
RCM-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HXOGlEPTB;MT6xNlExOiEQvF2=	MYnTRW5ITVJ?
MC116	NV;BUGcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2r1ZmlEPTB;MT6xN\|YzOSEQvF2=	NXzhcpZIW0GQR1XS
NCI-H1092	NYW3bZFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{mybGlEPTB;MT6xOVQxPiEQvF2=	NYn1Rnh6W0GQR1XS
EW-3	M2PtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInFS\|dKSzVyPUGuNVczOTJizszN	NFTWVFZUSU6JRWK=
HCT-116	NVLOW3htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37hdmlEPTB;MT6xO\|c2KM7:TR?=	M2jmVXNCVkeHUh?=
MC-IXC	NHy2XWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\hOWlEPTB;MT6xO\|g5OSEQvF2=	Ml;JV2FPT0WU
LB1047-RCC	NHz1UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwMUizNVIh\|ryP	NXfudJRPW0GQR1XS
VM-CUB-1	M2Sw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfOfZpRUUN3ME2xMlE6OTB6IN88US=>	MWrTRW5ITVJ?
NB5	Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonDTWM2OD1zLkG5PFU3KM7:TR?=	M4\3UHNCVkeHUh?=
SKG-IIIa	M2TBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO5W\|NKSzVyPUGuNlM1PjRizszN	NFfRO2dUSU6JRWK=
HO-1-N-1	M4PE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHQSZJKSzVyPUGuNlM5OzVizszN	NYjtTmU2W0GQR1XS
EFO-27	NYT2bFRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULFZZdoUUN3ME2xMlI2ODR\|IN88US=>	NYfJU29ZW0GQR1XS
MHH-NB-11	M2LDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHuTWM2OD1zLkK4N\|I6KM7:TR?=	MlP4V2FPT0WU
SW620	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\WdHVKSzVyPUGuNlkxOThizszN	MWTTRW5ITVJ?
MOLT-16	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlr1TWM2OD1zLkK5O\|k4KM7:TR?=	MmfGV2FPT0WU
NTERA-S-cl-D1	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFwM{G3OlEh\|ryP	M3HC[nNCVkeHUh?=
VA-ES-BJ	NYOyWVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{[x[WlEPTB;MT6zNlQ4PyEQvF2=	MlHZV2FPT0WU
HCC1419	NIfsSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjVOGNKSzVyPUGuN\|QxOjdizszN	NH\yXmlUSU6JRWK=
NCI-H69	M3rlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTFwM{SxNVIh\|ryP	NXW3dXBJW0GQR1XS
DEL	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\TTWM2OD1zLkO1NVYzKM7:TR?=	M2TGNnNCVkeHUh?=
LXF-289	M4LIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfwTWM2OD1zLkO1NlQh\|ryP	MXTTRW5ITVJ?
EW-11	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnUN2Y3UUN3ME2xMlM3ODJ4IN88US=>	NUTYU4JoW0GQR1XS
KP-4	M2O3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17zXWlEPTB;MT6zO\|A5PSEQvF2=	NF\Tb\|FUSU6JRWK=
NOS-1	NXfPSVJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7lW4dKSzVyPUGuOFEyQTRizszN	NETqS2hUSU6JRWK=
SK-NEP-1	NUHneJZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFwNEG2PVMh\|ryP	MoTyV2FPT0WU
LAMA-84	NXvT[I9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvBTGhMUUN3ME2xMlQ{QTR3IN88US=>	MoHkV2FPT0WU
ES5	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn75TWM2OD1zLkS0N{DPxE1?	M321SnNCVkeHUh?=
HuO9	NIXrVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWexdXRkUUN3ME2xMlQ2OzZ{IN88US=>	MVzTRW5ITVJ?
COLO-684	M{\SeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorBTWM2OD1zLkS2NVE5KM7:TR?=	M1z5WXNCVkeHUh?=
EW-24	NIrJS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYP2UFdHUUN3ME2xMlQ3PTNzIN88US=>	NFHzc4ZUSU6JRWK=
BV-173	MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrKTWM2OD1zLkS3NlkyKM7:TR?=	NViwWmF1W0GQR1XS
NCI-H1770	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPTTWM2OD1zLkS4OVM3KM7:TR?=	MniwV2FPT0WU
HuP-T4	NV7UXnV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PFfmlEPTB;MT60PVMh\|ryP	NYDyPFRJW0GQR1XS
TYK-nu	M1\5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonmTWM2OD1zLkS5PFUyKM7:TR?=	MoXGV2FPT0WU
YH-13	M3H3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFwNEm4PVQh\|ryP	NXG0S3g6W0GQR1XS
H4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDvVmhIUUN3ME2xMlUxQTF{IN88US=>	M1\CbHNCVkeHUh?=
OVCAR-8	NYPleo53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vLU2lEPTB;MT61OFQ4PyEQvF2=	M37pTHNCVkeHUh?=
NCI-H23	Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljYTWM2OD1zLkW0OlQ2KM7:TR?=	MnvMV2FPT0WU
ES7	NFnFdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zlZ2lEPTB;MT61OFc4OyEQvF2=	M{Ww[HNCVkeHUh?=
COR-L88	Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGP0NpVKSzVyPUGuOVY1OjRizszN	NUP2XIFiW0GQR1XS
TI-73	NFv5R\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXJ[HFqUUN3ME2xMlU6ODZizszN	NGH3bpFUSU6JRWK=
RT-112	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHiSZlRUUN3ME2xMlU6Ojh2IN88US=>	Ml[3V2FPT0WU
HuO-3N1	NHTzcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\4TXRiUUN3ME2xMlU6Ozh3IN88US=>	M2\OeHNCVkeHUh?=
HC-1	M1:3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFe1cFhKSzVyPUGuOVk5PjZizszN	MmLCV2FPT0WU
HT55	NYWxR4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTFwNkWxN\|Eh\|ryP	NVj5dlJJW0GQR1XS
IA-LM	MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPwUZpKSzVyPUGuOlkzPzhizszN	MYrTRW5ITVJ?
EM-2	NUjUTplET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTrRY9RUUN3ME2xMlcxODF2IN88US=>	M2rRVnNCVkeHUh?=
MHH-ES-1	NIjGS\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPkblZ7UUN3ME2xMlcxPDN3IN88US=>	M3[1fHNCVkeHUh?=
CAL-27	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTUTWM2OD1zLkewOlIyKM7:TR?=	NVPtbJVMW0GQR1XS
COLO-800	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4j0cWlEPTB;MT63NVE4QSEQvF2=	MXnTRW5ITVJ?
HCE-T	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\0UGhKSzVyPUGuO\|E2KM7:TR?=	M4\WbnNCVkeHUh?=
CAMA-1	MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\ITWM2OD1zLkexPVcyKM7:TR?=	M3nVOnNCVkeHUh?=
LOXIMVI	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rhO2lEPTB;MT63NlEyKM7:TR?=	NFnKZZlUSU6JRWK=
NH-12	M2mwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTFwN{K2PVEh\|ryP	MkDuV2FPT0WU
TCCSUP	NF3OSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NICwdFBKSzVyPUGuO\|I5OjlizszN	MXzTRW5ITVJ?
MDA-MB-361	NVTneY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrlTWM2OD1zLkezNVU4KM7:TR?=	NXvrdZdsW0GQR1XS
EW-16	M2DuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LBeGlEPTB;MT63OFExPyEQvF2=	NV60WFhXW0GQR1XS
SNU-423	NHnwfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTFwN{W4Nlch\|ryP	MWPTRW5ITVJ?
Daoy	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVKyc29tUUN3ME2xMlc3OzF7IN88US=>	NWTXcHVLW0GQR1XS
ES4	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXr3XmQ2UUN3ME2xMlc5PzRzIN88US=>	MWrTRW5ITVJ?
PFSK-1	NHnMWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHhZopDUUN3ME2xMlgxOzdizszN	MYXTRW5ITVJ?
ES3	M4XOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1K1VWlEPTB;MT64NlY5OSEQvF2=	NH3SOXNUSU6JRWK=
ONS-76	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33SXmlEPTB;MT64Nlg6PyEQvF2=	NVTU[FVPW0GQR1XS
JVM-3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTFwOEW0OVEh\|ryP	M1XlXHNCVkeHUh?=
OS-RC-2	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jBXWlEPTB;MT64O\|E2OSEQvF2=	MVrTRW5ITVJ?
COLO-320-HSR	M2rY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPyflVKSzVyPUGuPFgyQTdizszN	NX3YfnVXW0GQR1XS
HN	NVnHSIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTFwOEi3NlUh\|ryP	MVXTRW5ITVJ?
HT	NH30SXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jhe2lEPTB;MT64PFk1PyEQvF2=	NUfmcm91W0GQR1XS
LoVo	M131SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrBcVJKSzVyPUGuPFk5OSEQvF2=	MV;TRW5ITVJ?
CGTH-W-1	M3XJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFwOEm5OFYh\|ryP	NVHzWlhKW0GQR1XS
NB6	Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTFwOUGyPVgh\|ryP	NGPHbWNUSU6JRWK=
EW-22	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XYTmlEPTB;MT65Nlg5PyEQvF2=	NXzscFl2W0GQR1XS
ES6	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTFwOUO2N\|Eh\|ryP	NUm1TZN7W0GQR1XS
SCC-15	NXTzbWF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXqTWM2OD1zLkmzPFE6KM7:TR?=	NELEOXJUSU6JRWK=
HL-60	NV7MR5pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUH0dFYxUUN3ME2xMlk{QTB{IN88US=>	NXW1OHJjW0GQR1XS
human HOP-92	NEHud4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37IdmlEPTB;MT65OFA3PSEQvF2=	Ml;2V2FPT0WU
SW626	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLJTWM2OD1zLkm0PFk6KM7:TR?=	MUTTRW5ITVJ?
HEC-1	NHi0ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFwOUWzOkDPxE1?	NVrrNXlVW0GQR1XS
LB2241-RCC	MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwOUiyN\|Eh\|ryP	NWnXfZpUW0GQR1XS
Ramos-2G6-4C10	NHHBTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\4dGRKSzVyPUGuPVk1QTNizszN	MX;TRW5ITVJ?
A101D	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorWTWM2OD1{LkKwN\|A{KM7:TR?=	MojzV2FPT0WU
NCI-H446	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHZfoJKSzVyPUKuNFQ2QTlizszN	NYfXOJZYW0GQR1XS
SBC-5	NF3G[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTJwME[xOFch\|ryP	NXnyeJVjW0GQR1XS
HOS	NXP1Sm9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnKcGZKSzVyPUKuNFc3PTNizszN	M{LKenNCVkeHUh?=
K5	NFfib2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fKemlEPTB;Mj6wO\|gyOSEQvF2=	MV;TRW5ITVJ?
HLE	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTJwMEi1Nlkh\|ryP	M3jOUXNCVkeHUh?=
HSC-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjX[ZprUUN3ME2yMlEzQDl6IN88US=>	NUnMZ294W0GQR1XS
LCLC-97TM1	NF73RoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLRTWM2OD1{LkG0OVg{KM7:TR?=	M3G4e3NCVkeHUh?=
DMS-273	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTqdpIzUUN3ME2yMlE1QDN5IN88US=>	NGr5SWVUSU6JRWK=
TE-8	NXzFTXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVf1ZlhxUUN3ME2yMlE2PzZ3IN88US=>	MoHQV2FPT0WU
DSH1	NFnRT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4m5dWlEPTB;Mj6xOlM6QCEQvF2=	M1vmRnNCVkeHUh?=
CAL-51	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULXfndMUUN3ME2yMlE3Pjl7IN88US=>	M2nCOHNCVkeHUh?=
IST-SL1	NHPPbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJwMU[4OFQh\|ryP	M3XCVXNCVkeHUh?=
GCT	NYSwU3p5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTJwMUe3O{DPxE1?	MYjTRW5ITVJ?
SW948	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGX1WIJKSzVyPUKuNVg1PTZizszN	NWT4NGl6W0GQR1XS
NOMO-1	NH7SbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXrTWM2OD1{LkG5N\|E4KM7:TR?=	M3v4VHNCVkeHUh?=
C8166	M3ziSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz0TWM2OD1{LkKxN\|M1KM7:TR?=	NWPwe4FwW0GQR1XS
OC-314	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvXcY5CUUN3ME2yMlI{OjV7IN88US=>	MX\TRW5ITVJ?
CAL-39	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXEUYRKSzVyPUKuNlM3OjZizszN	M3;nW3NCVkeHUh?=
MDA-MB-453	NIP4bZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fhS2lEPTB;Mj6yOFI4PSEQvF2=	NHrzbYhUSU6JRWK=
A673	NVHyd\|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjqTZg{UUN3ME2yMlI2QDZ{IN88US=>	MV;TRW5ITVJ?
HTC-C3	NIS0VlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\tTWM2OD1{LkK2PFUh\|ryP	M37Ie3NCVkeHUh?=
NCI-H1666	M3\0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7XTWM2OD1{LkK4NVEyKM7:TR?=	M4DsZ3NCVkeHUh?=
PSN1	NFO2Z4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\xfpJKSzVyPUKuNlg6OTNizszN	MXHTRW5ITVJ?
GI-1	NFK2S4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDaTWM2OD1{LkOwOVQ{KM7:TR?=	MkXiV2FPT0WU
HuH-7	M3;IfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPue5NZUUN3ME2yMlMxPjN5IN88US=>	M{TKTnNCVkeHUh?=
JAR	NIjpZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3roUGlEPTB;Mj6zNVk5PyEQvF2=	NXH3cohLW0GQR1XS
5637	NXO4WmxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nvfGlEPTB;Mj6zNlEzQSEQvF2=	M1jvWHNCVkeHUh?=
GB-1	M1Oydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPFTWM2OD1{LkOyN\|M2KM7:TR?=	MlLxV2FPT0WU
KP-N-YS	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTJwM{K2NVUh\|ryP	MWjTRW5ITVJ?
OAW-42	M1W1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3s[WVKSzVyPUKuN\|M1OTZizszN	MYjTRW5ITVJ?
8-MG-BA	M4XRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoiyTWM2OD1{LkOzPVA3KM7:TR?=	M2\wOHNCVkeHUh?=
RH-18	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTJwM{WwNlIh\|ryP	M{G3WHNCVkeHUh?=
NCI-H1155	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJwM{[3NlUh\|ryP	MoDLV2FPT0WU
NB17	NYSxPXNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVq2XpE1UUN3ME2yMlM5OjR\|IN88US=>	NX;EbZFLW0GQR1XS
NCI-H1437	NI\pfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDsPI5KSzVyPUKuOFE5PzNizszN	NUD3cXA3W0GQR1XS
SN12C	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2G0TGlEPTB;Mj60N\|IyPCEQvF2=	NF\uS\|hUSU6JRWK=
HSC-3	NX63eXZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLuTWM2OD1{LkS0OVA6KM7:TR?=	NHj2eYRUSU6JRWK=
GAMG	M4fZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPjZWVKSzVyPUKuOFQ2PjFizszN	M2X2V3NCVkeHUh?=
HT-1080	NWD3VXFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;0TWM2OD1{LkS0PFY1KM7:TR?=	MWDTRW5ITVJ?
A549	Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\sTWM2OD1{LkS0PFk{KM7:TR?=	NYTGU5EzW0GQR1XS
KNS-62	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mke0TWM2OD1{LkS1NFYyKM7:TR?=	NHS1RnhUSU6JRWK=
YKG-1	NWDxfpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\CTWM2OD1{LkS1OFM4KM7:TR?=	NVjNbVJQW0GQR1XS
LU-134-A	NHK0[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NED3UJpKSzVyPUKuOFcxODhizszN	NX\FSGI2W0GQR1XS
FADU	NGqxUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTJwNEexOlIh\|ryP	MX\TRW5ITVJ?
TGBC11TKB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEj0e3FKSzVyPUKuOFcyPzdizszN	MmTGV2FPT0WU
HT-3	NID4UJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJwNEm1N\|Uh\|ryP	MlfTV2FPT0WU
NCI-H2170	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTMWGVFUUN3ME2yMlUxPTR7IN88US=>	NFHNWZRUSU6JRWK=
Mo-T	M{fUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\iW2lEPTB;Mj61NFkzPyEQvF2=	MU\TRW5ITVJ?
CCRF-CEM	NGDaS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTJwNUOwOFMh\|ryP	MmizV2FPT0WU
KU-19-19	Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHkTWM2OD1{LkWzOVE{KM7:TR?=	M2C2d3NCVkeHUh?=
NCI-H1048	NEjU[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;KVFdYUUN3ME2yMlU2ODJ3IN88US=>	NFfaPG5USU6JRWK=
KOSC-2	NIOwSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfITWM2OD1{LkW2NFc3KM7:TR?=	NInydXlUSU6JRWK=
A431	M3njVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{i2bGlEPTB;Mj61OlM{PSEQvF2=	M3\afnNCVkeHUh?=
COR-L23	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJwNUi1OlYh\|ryP	MY\TRW5ITVJ?
MKN28	NYXyVG9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvjXplKSzVyPUKuOVkxOzdizszN	NGLjSVVUSU6JRWK=
22RV1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELJO3RKSzVyPUKuOVkzPzRizszN	NFKybldUSU6JRWK=
ABC-1	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TPTWlEPTB;Mj62NFQ3KM7:TR?=	NEPNNYpUSU6JRWK=
NCI-H2126	NWrYSVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfOTWM2OD1{Lk[wPVg1KM7:TR?=	MV7TRW5ITVJ?
DoTc2-4510	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofPTWM2OD1{Lk[yNVg2KM7:TR?=	MVnTRW5ITVJ?
SCC-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJwNkOwNVIh\|ryP	M3rEbnNCVkeHUh?=
NCI-H661	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vEWmlEPTB;Mj62OFA5PSEQvF2=	MkS0V2FPT0WU
RPMI-2650	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;ER3NVUUN3ME2yMlY1OTR\|IN88US=>	MYfTRW5ITVJ?
NCI-H510A	NUezdYM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTn[mM2UUN3ME2yMlY1PDJ4IN88US=>	MXHTRW5ITVJ?
BPH-1	NH;MNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkj5TWM2OD1{Lk[1PFUh\|ryP	MVHTRW5ITVJ?
M14	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrYTWM2OD1{Lk[2PVk{KM7:TR?=	NV3tc\|ExW0GQR1XS
G-402	NWrnWoFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DkZWlEPTB;Mj63NFQ2OSEQvF2=	NIC5PJJUSU6JRWK=
AsPC-1	NXOwZZlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XQWGlEPTB;Mj63NVE4KM7:TR?=	NVjob4lrW0GQR1XS
NB12	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PwNGlEPTB;Mj63NVcyKM7:TR?=	M1m0fXNCVkeHUh?=
SK-HEP-1	NXPWOmRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELRXmNKSzVyPUKuO\|Q{QTFizszN	M2P2SnNCVkeHUh?=
U-266	NVL6cVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJwN{exNlEh\|ryP	NV7ydlBVW0GQR1XS
AM-38	M3;xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\SVlVKSzVyPUKuO\|c{PTVizszN	NEjNV5pUSU6JRWK=
PC-14	M2Ln[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\0e2lEPTB;Mj64NFUyKM7:TR?=	Mmn1V2FPT0WU
EGI-1	NWPLToFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJwOEG3OFMh\|ryP	M4DPS3NCVkeHUh?=
LS-411N	NF;DN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\hVm5KSzVyPUKuPFI{OyEQvF2=	MoLqV2FPT0WU
BFTC-905	MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTtTWM2OD1{Lki1OVI{KM7:TR?=	MXzTRW5ITVJ?
CaR-1	NGn1NnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPB[YJUUUN3ME2yMlg3KM7:TR?=	M1zTUnNCVkeHUh?=
NCI-H292	M3HJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TI[mlEPTB;Mj64OlU6PiEQvF2=	M13TWnNCVkeHUh?=
8305C	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTJwOE[2OFUh\|ryP	NFPIdVdUSU6JRWK=
SNU-449	NXX1cIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfIfmROUUN3ME2yMlg6OTh{IN88US=>	NX\VXotmW0GQR1XS
LCLC-103H	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7GTWM2OD1{LkmwOFM5KM7:TR?=	M3vWcnNCVkeHUh?=
SW1573	NFTBZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTJwOU[wPFIh\|ryP	MUPTRW5ITVJ?
MLMA	NVeyUm5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPGTWM2OD1{Lkm2O\|E4KM7:TR?=	NXnhRllUW0GQR1XS
NCI-H1355	MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljrTWM2OD1\|LkCwO\|k3KM7:TR?=	MXTTRW5ITVJ?
RMG-I	NXTaN2xHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTNwMEK1PVIh\|ryP	NVTwOnptW0GQR1XS
BB65-RCC	NELJOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLrVnRKSzVyPUOuNFM{OTRizszN	M3LXXXNCVkeHUh?=
PC-3	M{L2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrVTWM2OD1\|LkCzPFc1KM7:TR?=	Mor1V2FPT0WU
SF268	NFL6VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\mTWM2OD1\|LkC0OVI{KM7:TR?=	MnviV2FPT0WU
NCI-H810	NWT3d3JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTNwMES4NlMh\|ryP	NHn4O5RUSU6JRWK=
MEG-01	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPnTWM2OD1\|LkC2NVY1KM7:TR?=	NVToSm5nW0GQR1XS
SW13	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrEc\|dKSzVyPUOuNFc5PDdizszN	M3y3SHNCVkeHUh?=
RH-1	Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPKbXpwUUN3ME2zMlExOjd6IN88US=>	MWrTRW5ITVJ?
GT3TKB	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTNwMUGyPFMh\|ryP	MoLRV2FPT0WU
TK10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTNwMUO3NlQh\|ryP	NGHvfGVUSU6JRWK=
T-24	M2PMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGG1cGVKSzVyPUOuNVUxPyEQvF2=	MWnTRW5ITVJ?
A498	NYrTWVd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfueHhEUUN3ME2zMlIxQDdzIN88US=>	NYizWlRoW0GQR1XS
GR-ST	M2nRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;hVGlEPTB;Mz6yNlE{QSEQvF2=	M1zsSnNCVkeHUh?=
LB2518-MEL	NF\RUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;6TWM2OD1\|LkKyN\|k5KM7:TR?=	MV3TRW5ITVJ?
T47D	NWLycnRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXabJNKSzVyPUOuNlM3OjdizszN	M{LTXnNCVkeHUh?=
NCI-H1651	M4\5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHj0NJVKSzVyPUOuNlQ3PDRizszN	MV3TRW5ITVJ?
EC-GI-10	NF;KV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\0bmpKSzVyPUOuNlYyPTNizszN	NFrTRlNUSU6JRWK=
HT-29	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTNwMk[2NVQh\|ryP	MYLTRW5ITVJ?
GI-ME-N	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTNwMkm1NVEh\|ryP	MYTTRW5ITVJ?
SW756	M3fzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYm1XYdYUUN3ME2zMlI6PjJ7IN88US=>	NFftb4RUSU6JRWK=
RKO	NIHybJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PVO2lEPTB;Mz6zNFc2PyEQvF2=	NVHqWFBsW0GQR1XS
NCI-H1563	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\RNnBKSzVyPUOuN\|MxOThizszN	M3jG[nNCVkeHUh?=
DJM-1	NWjTWXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTNwM{e2O\|Qh\|ryP	NWLRclB6W0GQR1XS
L-428	NHexU\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWX5ZW5yUUN3ME2zMlQxODR3IN88US=>	NWnLd\|ZEW0GQR1XS
NCI-H2122	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX[3TZlXUUN3ME2zMlQyOzF{IN88US=>	Ml\uV2FPT0WU
Ca-Ski	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGn3bWpKSzVyPUOuOFU1OyEQvF2=	MXjTRW5ITVJ?
639-V	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGf0Z5FKSzVyPUOuOFYxPTdizszN	NHzpVnFUSU6JRWK=
SW1116	MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHZZ5FqUUN3ME2zMlQ3OjZ7IN88US=>	MkfrV2FPT0WU
DMS-114	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrzTWM2OD1\|LkS3NFY3KM7:TR?=	M37menNCVkeHUh?=
MZ2-MEL	MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTNwNEe2PFEh\|ryP	MkHTV2FPT0WU
COLO-829	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfxTWM2OD1\|LkWwNFc{KM7:TR?=	NXm3[45TW0GQR1XS
J82	NIf5S5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWD2V4VlUUN3ME2zMlUxPTdizszN	MXrTRW5ITVJ?
EW-13	M3LvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTiTWM2OD1\|LkWyOVEh\|ryP	MoW1V2FPT0WU
RXF393	NWG0UFlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfXTXl7UUN3ME2zMlU{Ojl2IN88US=>	MX;TRW5ITVJ?
CAL-62	Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPhTWM2OD1\|LkW0OVE1KM7:TR?=	MYrTRW5ITVJ?
OCUB-M	M3iyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPmTWM2OD1\|LkW0OlY2KM7:TR?=	NV;QVI9TW0GQR1XS
BT-474	NHv6PYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfB[op5UUN3ME2zMlY{OzFizszN	MULTRW5ITVJ?
KYSE-180	MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\2eHdSUUN3ME2zMlY{Ozd{IN88US=>	M3HrOnNCVkeHUh?=
NCI-H650	M1HMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LsR2lEPTB;Mz62OFI5PyEQvF2=	MYfTRW5ITVJ?
Detroit562	M4PWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nxdWlEPTB;Mz62OVAzOiEQvF2=	M1:4dXNCVkeHUh?=
SW48	M4THRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3qTWM2OD1\|Lk[1OlU4KM7:TR?=	NH3iVFVUSU6JRWK=
KYSE-450	NXHVe4dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUD5N5JpUUN3ME2zMlY5PTh{IN88US=>	MWrTRW5ITVJ?
KYSE-510	NGHwem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTNwN{KxPFEh\|ryP	NYHjU2l4W0GQR1XS
GP5d	M{jrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLJTWM2OD1\|LkeyPVUh\|ryP	MXzTRW5ITVJ?
RPMI-7951	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTNwN{S3NlMh\|ryP	MkTwV2FPT0WU
Becker	NIX3XGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\ObWlEPTB;Mz63OVAyOiEQvF2=	NF6zNJNUSU6JRWK=
WM-115	NHLXWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fyPGlEPTB;Mz63PFE6PSEQvF2=	NEDFNYJUSU6JRWK=
G-401	NXPyRnFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\1OFNZUUN3ME2zMlc6ODh3IN88US=>	M33COXNCVkeHUh?=
PANC-08-13	MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzubHpLUUN3ME2zMlc6PjB{IN88US=>	NGHCNJlUSU6JRWK=
SW982	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonUTWM2OD1\|LkiwOVUyKM7:TR?=	NUnWTmJPW0GQR1XS
D-263MG	M1PtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\kZ2lEPTB;Mz64NlA2OSEQvF2=	NIixdldUSU6JRWK=
KM-H2	NH7oPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXHNWJKSzVyPUOuPFI3OjRizszN	M3;ZW3NCVkeHUh?=
SK-MEL-3	MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3rTWM2OD1\|LkiyPFQyKM7:TR?=	NWLUTFRiW0GQR1XS
NCI-H1581	NGq2fWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[5bFhKSzVyPUOuPFQ1QDhizszN	NYHHWmY6W0GQR1XS
LS-123	M1rOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\FTWM2OD1\|Lki3PVA6KM7:TR?=	MUDTRW5ITVJ?
CAKI-1	MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\JW2lEPTB;Mz64PVA2OiEQvF2=	MXvTRW5ITVJ?
MEL-JUSO	NEX6RnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFT0RphKSzVyPUOuPFkyPTNizszN	NHHPdFFUSU6JRWK=
HCE-4	NWjXWIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmO5TWM2OD1\|LkmxOlY{KM7:TR?=	Ml7LV2FPT0WU
TE-10	MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLRTWM2OD1\|LkmyNFEh\|ryP	NFzzNmdUSU6JRWK=
OVCAR-4	M1T2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfqTWM2OD1\|LkmyPFg6KM7:TR?=	NFnS[ZBUSU6JRWK=
ETK-1	M3\6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIX4UW9KSzVyPUOuPVQ3OzVizszN	MV;TRW5ITVJ?
A2780	NEmyWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mny3TWM2OD12LkC1PVY3KM7:TR?=	NYTEOG55W0GQR1XS
LU-65	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTRwMEe2N\|Mh\|ryP	MVfTRW5ITVJ?
BHY	NGHYSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjOco1KSzVyPUSuNVI1QTVizszN	M2jtUHNCVkeHUh?=
COR-L105	NHHVdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHa[3RKSzVyPUSuNVMxPTFizszN	NW\ybG82W0GQR1XS
CAL-12T	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFj0bZlKSzVyPUSuNVMyODNizszN	MUHTRW5ITVJ?
SCH	NWnhXXEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zo[GlEPTB;ND6xOVc1OyEQvF2=	M3PxVnNCVkeHUh?=
CW-2	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPKTWM2OD12LkG5NFAyKM7:TR?=	NGi4T3BUSU6JRWK=
HCC1806	NIHpZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\HVJlVUUN3ME20MlIxOzF{IN88US=>	MojUV2FPT0WU
KP-N-YN	NUDlNml1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjh[G9KSzVyPUSuNlA6OjdizszN	NYnIe3JqW0GQR1XS
T98G	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nMXWlEPTB;ND6yNlE2PyEQvF2=	NWn0ZXhCW0GQR1XS
CAL-54	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXuUJdzUUN3ME20MlIzOzhzIN88US=>	MlHXV2FPT0WU
CAL-33	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjEU2xuUUN3ME20MlI{ODZ2IN88US=>	MXrTRW5ITVJ?
SNU-C2B	NYHUNmVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHVTWM2OD12LkK0O\|Y6KM7:TR?=	NIjoOZlUSU6JRWK=
NUGC-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn74TWM2OD12LkK1OVA2KM7:TR?=	MWXTRW5ITVJ?
DOK	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XUWWlEPTB;ND6yOlU6OyEQvF2=	NULlRlIyW0GQR1XS
MMAC-SF	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVT6PWVjUUN3ME20MlI3QDV7IN88US=>	MUXTRW5ITVJ?
KYSE-70	NIfoT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{f5cmlEPTB;ND6yPVM1KM7:TR?=	NHrnUlNUSU6JRWK=
A204	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHUNWlKSzVyPUSuN\|U5ODNizszN	MX\TRW5ITVJ?
SCC-25	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTRwM{W4NVkh\|ryP	MorzV2FPT0WU
EPLC-272H	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTRwM{i5OUDPxE1?	M{nWRnNCVkeHUh?=
CAL-120	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXGSFNKSzVyPUSuN\|g6QTJizszN	NGflXFFUSU6JRWK=
LS-513	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnzdWpKSzVyPUSuOFIyQThizszN	M4DPfnNCVkeHUh?=
CAPAN-1	NXLR[2tKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7YXIlKSzVyPUSuOFI{QDJizszN	MXvTRW5ITVJ?
ESS-1	NXrUeWc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLmTWM2OD12LkSyO\|I1KM7:TR?=	M2nJW3NCVkeHUh?=
GMS-10	M4HxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7TTWM2OD12LkSyPFE6KM7:TR?=	MXPTRW5ITVJ?
NCI-N87	M4C3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrJTWM2OD12LkWwPFY5KM7:TR?=	M1PtVnNCVkeHUh?=
HMV-II	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTRwNUG3N{DPxE1?	NH;qTVZUSU6JRWK=
COLO-741	NYjMZlliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn0OFVKSzVyPUSuOVU6QTRizszN	M1f5[HNCVkeHUh?=
MKN45	M1\l[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDnTWM2OD12LkW3O\|MzKM7:TR?=	NGTuemVUSU6JRWK=
OAW-28	MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVS2clVwUUN3ME20MlU5Ozl6IN88US=>	NUTMT2VXW0GQR1XS
OCI-AML2	M4mxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHz1RVhKSzVyPUSuOlUzOzhizszN	NHfqZ4hUSU6JRWK=
MDA-MB-231	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITXVpVKSzVyPUSuO\|AzPDNizszN	NEfmS4dUSU6JRWK=
NCI-H1648	MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLSTWM2OD12LkeyNlc{KM7:TR?=	MkPDV2FPT0WU
NCI-H1792	MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofhTWM2OD12Lke2NVA4KM7:TR?=	NYDIfJhnW0GQR1XS
GCIY	NI\Re45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTRwN{e0NlQh\|ryP	NYftUmRHW0GQR1XS
Hs-578-T	NI\aeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDLTWM2OD12Lke3OlU2KM7:TR?=	M4XGN3NCVkeHUh?=
SW962	M2\rUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TtVGlEPTB;ND63PFAyOSEQvF2=	MVLTRW5ITVJ?
NCI-H630	M4C0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\kVYFKSzVyPUSuO\|gxQDFizszN	M4XGZXNCVkeHUh?=
786-0	NWHTTmN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvrSpBrUUN3ME20Mlc5Pzd\|IN88US=>	NVj4N3pMW0GQR1XS
FTC-133	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4f4UWlEPTB;ND63PVI3OyEQvF2=	MY\TRW5ITVJ?
BT-20	NGjjPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDX[2ZKSzVyPUSuO\|k1OjlizszN	M{Hte3NCVkeHUh?=
Mewo	M3LKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rOcGlEPTB;ND64NVc1PyEQvF2=	M{TNXXNCVkeHUh?=
SW780	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfmS2g3UUN3ME20Mlg2PzZ4IN88US=>	M3nWZ3NCVkeHUh?=
OE33	NETxbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Wy[2lEPTB;ND64O\|cyOyEQvF2=	Mn33V2FPT0WU
HCC1569	MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnj6TWM2OD12Lki4OFU5KM7:TR?=	NVzoPGVYW0GQR1XS
TE-6	M3nGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTRwOUO5O\|ch\|ryP	MUnTRW5ITVJ?
SK-N-FI	NV[xT5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLsdZlKSzVyPUSuPVQ1OjFizszN	MWPTRW5ITVJ?
PANC-03-27	M2fjd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTRwOUm5OlIh\|ryP	MXXTRW5ITVJ?
MCF7	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvjVWh[UUN3ME21MlAxPzN6IN88US=>	NUG5[pFNW0GQR1XS
UACC-257	M4\Bemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT2bmE1UUN3ME21MlAzQDR3IN88US=>	NIeyRoFUSU6JRWK=
SW1088	NH7VVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX6zb\|J2UUN3ME21MlAzQTR2IN88US=>	M1j4WnNCVkeHUh?=
A704	M4jBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHnXpZHUUN3ME21MlA{ODZizszN	MX;TRW5ITVJ?
A2058	NH3zXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLBTWM2OD13LkC1PVA5KM7:TR?=	M2HFSnNCVkeHUh?=
Calu-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LJfWlEPTB;NT6wOlQ2OiEQvF2=	M1HpbnNCVkeHUh?=
RERF-LC-MS	NYLwXopET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfhXFJsUUN3ME21MlA3QTB\|IN88US=>	M2rnXnNCVkeHUh?=
AU565	M13BfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7WTWM2OD13LkC5O\|AzKM7:TR?=	MXXTRW5ITVJ?
DMS-79	NEW2Uo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPhbGx{UUN3ME21MlE{QDh\|IN88US=>	M2rSSnNCVkeHUh?=
DK-MG	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHtNWpKSzVyPUWuNVg1OzhizszN	MkSyV2FPT0WU
HuCCT1	NHvJOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTVwMkO4OVYh\|ryP	NVnaRYpEW0GQR1XS
HT-144	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfTOIxKSzVyPUWuNlQ6QDdizszN	MoDDV2FPT0WU
M059J	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\POo1YUUN3ME21MlI2PzZizszN	M3LGUHNCVkeHUh?=
COLO-792	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHEbW52UUN3ME21MlI3OzV4IN88US=>	NVj3RpJjW0GQR1XS
SF539	NXrEfIRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTvTWM2OD13LkK2OlMzKM7:TR?=	MX7TRW5ITVJ?
SK-UT-1	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HhbWlEPTB;NT6yO\|c2OSEQvF2=	M4C3cXNCVkeHUh?=
NCI-H1703	NIrKO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDoWG5KSzVyPUWuN\|U5OjZizszN	MVrTRW5ITVJ?
SW837	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmm1TWM2OD13LkO3PFc5KM7:TR?=	MWHTRW5ITVJ?
U251	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlT4TWM2OD13LkO5NFk3KM7:TR?=	NEflU4JUSU6JRWK=
SW1710	NHHnUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrLTWM2OD13LkSxOVU1KM7:TR?=	NXrwS5cxW0GQR1XS
NCI-H1299	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1O4eWlEPTB;NT60OlM{PSEQvF2=	M33m[nNCVkeHUh?=
RVH-421	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;reFE{UUN3ME21MlQ6QTB6IN88US=>	Ml;kV2FPT0WU
UM-UC-3	NVH0d3ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPTUFhKUUN3ME21MlYzPjVzIN88US=>	M3y4fXNCVkeHUh?=
MDA-MB-175-VII	M1rIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljVTWM2OD13Lk[0NFQyKM7:TR?=	MknBV2FPT0WU
KYSE-270	NVXrOI12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTVwNk[wN\|Eh\|ryP	NIr5cZJUSU6JRWK=
COLO-668	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvWcYlwUUN3ME21MlcyOzJizszN	NEe3e2FUSU6JRWK=
LN-405	M3nCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXT5WFIxUUN3ME21Mlc{ODh3IN88US=>	NEn0SIlUSU6JRWK=
HT-1376	NXHVTlBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[4eWZuUUN3ME21Mlc5ODV{IN88US=>	M2HvSHNCVkeHUh?=
769-P	NGe3NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mor6TWM2OD13Lki2O\|E5KM7:TR?=	MWXTRW5ITVJ?
HuP-T3	NF;SemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTV[phQUUN3ME21Mlg5Pjd5IN88US=>	MYDTRW5ITVJ?
MDA-MB-415	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWO2VGFKUUN3ME21MlkzOTN7IN88US=>	M1jLVHNCVkeHUh?=
MKN7	NIPFcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTVwOUi4JO69VQ>?	MXrTRW5ITVJ?
KS-1	NYLrSFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXIVIVKSzVyPUWuPVg5OzZizszN	NHKxZnRUSU6JRWK=
647-V	NVvCO3ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoOwTWM2OD13Lkm5NVQ5KM7:TR?=	MXPTRW5ITVJ?
COLO-679	MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjXTWM2OD14LkCwNlU2KM7:TR?=	NVXw[Zc6W0GQR1XS
AN3-CA	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTZwMEO0OFEh\|ryP	MlvJV2FPT0WU
C32	NHXHXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITmZ4VKSzVyPU[uNVMxOzRizszN	MmHUV2FPT0WU
KM12	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\pZmlEPTB;Nj6yOFA6QSEQvF2=	NEDSPWhUSU6JRWK=
KINGS-1	NWjteZJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7pTWM2OD14LkK2NVUzKM7:TR?=	MUDTRW5ITVJ?
KYSE-410	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTZwM{C2OFUh\|ryP	NF3De4xUSU6JRWK=
HPAF-II	NF;le4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TrXWlEPTB;Nj6zOVQ5KM7:TR?=	M2f2bnNCVkeHUh?=
LAN-6	MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3j5SGlEPTB;Nj60PVY{OSEQvF2=	NX7xSZp4W0GQR1XS
LU-99A	M1\F[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7MXXpPUUN3ME22MlU2QTh7IN88US=>	MnnzV2FPT0WU
SJSA-1	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjEd4hKSzVyPU[uOVY{PDdizszN	Mn;hV2FPT0WU
MSTO-211H	NHrHOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XLcGlEPTB;Nj63NlI{OyEQvF2=	MnKzV2FPT0WU
SW900	NF[2dnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHi[nNZUUN3ME22Mlc3OjJzIN88US=>	MVnTRW5ITVJ?
LNCaP-Clone-FGC	M2fscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrDTWM2OD14LkiwOFA{KM7:TR?=	NWPyUXR6W0GQR1XS
OMC-1	NIrXR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTZwOEW0NFIh\|ryP	NXjIdFVqW0GQR1XS
IST-MEL1	M3fs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHxeWtKSzVyPU[uPFk3PjlizszN	MV\TRW5ITVJ?
TE-9	NYHMVVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY[2Wo5xUUN3ME22Mlg6QDR5IN88US=>	NU\BeFA5W0GQR1XS
NCI-H2030	M3XJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rjdGlEPTB;Nj65NVIzPiEQvF2=	MUnTRW5ITVJ?
BFTC-909	NYLncnJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTdwMEC2OFEh\|ryP	MmnTV2FPT0WU
NCI-SNU-5	M1jrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrnOFRyUUN3ME23MlAzOTV7IN88US=>	NXK2PVJpW0GQR1XS
TE-5	MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXZdJVKSzVyPUeuNFI5QDFizszN	M2DrOnNCVkeHUh?=
SK-MES-1	NXHw[5RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfWcoxKSzVyPUeuNFU1OjdizszN	MVjTRW5ITVJ?
SHP-77	NEXiT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTdwMUO5OVIh\|ryP	M{SzXXNCVkeHUh?=
NCI-H1623	NYjzb4R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;2TWM2OD15LkG0NFczKM7:TR?=	MorKV2FPT0WU
TE-11	NGXndY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVq3[nFRUUN3ME23MlE2OTh2IN88US=>	Ml;zV2FPT0WU
EKVX	M1Gxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Xwb2lEPTB;Nz6xPVI3PyEQvF2=	MVvTRW5ITVJ?
OVCAR-3	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml2xTWM2OD15LkKxNVM{KM7:TR?=	NFv3OWpUSU6JRWK=
C3A	NYDzVI9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7TeppxUUN3ME23MlM1PTJizszN	MVnTRW5ITVJ?
CFPAC-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TjT2lEPTB;Nz6zOlIzOiEQvF2=	MlrwV2FPT0WU
MG-63	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDXTWM2OD15LkSxPFQ6KM7:TR?=	M4TaeHNCVkeHUh?=
KYSE-140	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDkTWM2OD15LkS0NFYyKM7:TR?=	MXfTRW5ITVJ?
MPP-89	M{jZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTdwNUm3Nlkh\|ryP	MoHlV2FPT0WU
COLO-824	NHnhT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD5TWM2OD15LkeyPFY{KM7:TR?=	MoTpV2FPT0WU
SiHa	MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXFRlFZUUN3ME23Mlg{PzB5IN88US=>	MlywV2FPT0WU
SNU-387	NG\XSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTdwOEWzOFch\|ryP	Mme1V2FPT0WU
A172	NG[4SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHFNJV2UUN3ME23Mlg3OTd{IN88US=>	MoT3V2FPT0WU
COLO-680N	NUOyT5ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{[wPWlEPTB;Nz65NVc{KM7:TR?=	M{jCV3NCVkeHUh?=
HCC1395	M4SwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LyTmlEPTB;OD6wOVQ2OiEQvF2=	MWDTRW5ITVJ?
NCI-H28	NVvGNZZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXZV4lKSzVyPUiuNFU6PjNizszN	NGLETmVUSU6JRWK=
LC-2-ad	MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXCTWM2OD16LkKxPVM4KM7:TR?=	MYXTRW5ITVJ?
S-117	NXXnbpk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRThwMkWzOVMh\|ryP	NYrYd\|g1W0GQR1XS
NCI-H1838	MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPDO5FtUUN3ME24MlI2PzhzIN88US=>	NUHIZ5R[W0GQR1XS
PANC-10-05	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE[1eYpKSzVyPUiuN\|cxPDdizszN	MoXsV2FPT0WU
KALS-1	M1zFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fNU2lEPTB;OD61NFkzQCEQvF2=	NYfEbIRXW0GQR1XS
LS-1034	NELEU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRThwNUe0N\|ch\|ryP	M3jM[nNCVkeHUh?=
TGBC1TKB	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLhTWM2OD16LkezOVM2KM7:TR?=	NX\oW5k2W0GQR1XS
OE19	NUDHbW5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\0T2xKSzVyPUiuO\|YzPjJizszN	MoizV2FPT0WU
D-502MG	NH7nRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnz4TWM2OD16Lke2PVk1KM7:TR?=	M3L2eHNCVkeHUh?=
JEG-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHaT3Y6UUN3ME24Mlc5PjF6IN88US=>	MlfmV2FPT0WU
DBTRG-05MG	M3PiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHe4ZmtKSzVyPUiuPFc2PjVizszN	NF[2RVFUSU6JRWK=
ME-180	M4\Z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fZemlEPTB;OT6wOlczPSEQvF2=	MUjTRW5ITVJ?
NCI-H1573	NFrleZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjsUpZKSzVyPUmuNVA2OzJizszN	MkTrV2FPT0WU
HCC2998	M1yyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LzR2lEPTB;OT6xN\|Y5OSEQvF2=	MY\TRW5ITVJ?
ACHN	NW[2WppCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XIR2lEPTB;OT6yOFk4PSEQvF2=	MoGwV2FPT0WU
D-392MG	M4D2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTlwMkW3NVUh\|ryP	MVrTRW5ITVJ?
no-11	M4LiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXvTWM2OD17LkK2NFI5KM7:TR?=	NHriVWhUSU6JRWK=
KLE	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTlwM{KyN\|Ih\|ryP	M2PDNnNCVkeHUh?=
Calu-6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTlwM{e1Nlgh\|ryP	MYPTRW5ITVJ?
LB831-BLC	M1jacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\hbnVsUUN3ME25MlQ2OTdzIN88US=>	NV61PYxqW0GQR1XS
SW684	NUS5dnZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEflVnFKSzVyPUmuOFYyOTZizszN	M2jXSXNCVkeHUh?=
SH-4	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXkTWM2OD17LkS5N\|Y1KM7:TR?=	MXPTRW5ITVJ?
IST-MES1	NWfLcVBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jLOGlEPTB;OT61NVY1PCEQvF2=	NIm1NndUSU6JRWK=
Saos-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPEZXp3UUN3ME25MlUzOTl3IN88US=>	NELENoxUSU6JRWK=
NCI-H2087	NHW4[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjKPIpzUUN3ME25MlY4OzV{IN88US=>	M3\yRXNCVkeHUh?=
SCC-9	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFiwWm1KSzVyPUmuO\|E5OTZizszN	M33qd3NCVkeHUh?=
MFE-280	NXyy[GpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDudWVKSzVyPUmuO\|I4QDVizszN	M2e4NnNCVkeHUh?=
BEN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jN[GlEPTB;OT64NlE2QSEQvF2=	NVznXFBVW0GQR1XS
CP50-MEL-B	NH6wUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fLdGlEPTB;OT65NlQ{OiEQvF2=	NVvhcXlNW0GQR1XS
SK-MEL-28	M2PVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFyLkCxPVMh\|ryP	NWTyS2JXW0GQR1XS
NCI-H2452	M3\jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnjWIk5UUN3ME2xNE4yPiEQvF2=	MYPTRW5ITVJ?
NCI-H1395	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknyTWM2OD1zMD6xO\|gh\|ryP	NV[0TXM1W0GQR1XS
NCI-H2052	NVjycVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzsTWM2OD1zMD6xPFgzKM7:TR?=	M{T5PHNCVkeHUh?=
A375	Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHuOolNUUN3ME2xNE4zPDV{IN88US=>	NXzERYs5W0GQR1XS
HCC38	M2qwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk[xTWM2OD1zMD6zNlIh\|ryP	NWqwN3pLW0GQR1XS
LK-2	NY\IUZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVKyNGduUUN3ME2xNE41OjB6IN88US=>	M{TrPHNCVkeHUh?=
SF126	M4DL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTFyLkS3Nlch\|ryP	M3fHNHNCVkeHUh?=
SK-MEL-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTFyLke4N\|gh\|ryP	NXjhWZI2W0GQR1XS
ACN	NFzxN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvHTWM2OD1zMD64Olc6KM7:TR?=	NIXV[HNUSU6JRWK=
BB30-HNC	NFTvXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkn5TWM2OD1zMD64O\|EyKM7:TR?=	NI\xUZVUSU6JRWK=
NCI-H747	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fo[GlEPTB;MUCuPFc1PiEQvF2=	MUfTRW5ITVJ?
KYSE-150	M3vQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXRTWM2OD1zMT6wN\|g4KM7:TR?=	M4rSRnNCVkeHUh?=
D-247MG	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFz5VGJKSzVyPUGxMlExODlizszN	MnfIV2FPT0WU
BxPC-3	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTFzLkO3OFch\|ryP	NXq2OpFyW0GQR1XS
SK-MEL-30	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\ZR48yUUN3ME2xNU41ODd7IN88US=>	MV3TRW5ITVJ?
CAS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTFzLkSxNFkh\|ryP	NFruRmtUSU6JRWK=
no-10	M{SyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfHSm1KSzVyPUGyMlEzOTdizszN	NV31PGtSW0GQR1XS
NCI-H2405	M3jwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2ToVWlEPTB;MUKuNlA{PiEQvF2=	NF;USpFUSU6JRWK=
KGN	M2DqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVS5d25LUUN3ME2xNk4zQTBzIN88US=>	MlnrV2FPT0WU
BB49-HNC	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTF{LkO5OVYh\|ryP	NHP0XmZUSU6JRWK=
NCI-H1693	M330[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnVXZlKSzVyPUGyMlU5OTZizszN	Mn\ZV2FPT0WU
RO82-W-1	NIXGWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX4TWM2OD1zMz6wOlQ6KM7:TR?=	MYTTRW5ITVJ?
CAL-85-1	NFfySVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFL2bWdKSzVyPUGzMlQ{QTlizszN	Moe3V2FPT0WU
H-EMC-SS	NXvPTmI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYeyNI15UUN3ME2xN{46OTB2IN88US=>	MlGzV2FPT0WU
SW1783	M4rsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NES2fWhKSzVyPUG0MlI{QTFizszN	M4C4UHNCVkeHUh?=
LB771-HNC	NXrEOnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIK3RndKSzVyPUG0MlQyQSEQvF2=	MWrTRW5ITVJ?
HCC70	M2PudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlGxTWM2OD1zND60NlM{KM7:TR?=	M{W3cnNCVkeHUh?=
KNS-81-FD	MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXM[nlNUUN3ME2xOE44ODR3IN88US=>	M1u5TnNCVkeHUh?=
KYSE-520	NXL3UIp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonRTWM2OD1zND65Nlch\|ryP	MYPTRW5ITVJ?
TGBC24TKB	NYKxfVd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTF2Lkm1N\|kh\|ryP	NFfuT3BUSU6JRWK=
SNB75	M{\Kb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\XRYdJUUN3ME2xOU4xPzJ7IN88US=>	NVT4XI1nW0GQR1XS
SW872	NFXSfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrLVZdKSzVyPUG1MlIzOThizszN	NWDw[G4yW0GQR1XS
U031	NXnxV2JZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXT0Z2xJUUN3ME2xOU45ODJ6IN88US=>	NX7SZmJPW0GQR1XS
ChaGo-K-1	NXvtN41rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTF3LkizOVkh\|ryP	M2nxT3NCVkeHUh?=
NCI-H441	NI\XfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTF4LkCwN\|kh\|ryP	NHfnO2tUSU6JRWK=
TE-12	M1fxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEGwenVKSzVyPUG2MlE5PzNizszN	NFfBVHhUSU6JRWK=
NCI-H1755	NFHsd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTF4LkW3N{DPxE1?	MWDTRW5ITVJ?
KNS-42	M3f0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYqxW5FHUUN3ME2xOk43PTh7IN88US=>	MmjwV2FPT0WU
SK-PN-DW	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTF5LkSyNFEh\|ryP	NHyySW9USU6JRWK=
NCI-H226	NETreFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\2XWlEPTB;MUeuPVM1PSEQvF2=	MUDTRW5ITVJ?
K-562	NYP6N4VWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;GUZhRUUN3ME2xPE43OzF5IN88US=>	M2DDT3NCVkeHUh?=
A388	NGDHTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFroWYJKSzVyPUG5MlA{ODNizszN	M1LBXnNCVkeHUh?=
ZR-75-30	NV:5SXJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjCPY1KSzVyPUG5MlA6PjhizszN	Mk\yV2FPT0WU
LU-135	NFPDNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXi[GlKSzVyPUG5MlI3OzZizszN	NYHnbZFSW0GQR1XS
NCI-H2029	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\kSWlEPTB;MUmuOlAzOSEQvF2=	NWXlWnRuW0GQR1XS
HT-1197	M4O5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX6UHBKSzVyPUG5MlkzOjdizszN	NULtZ4ZwW0GQR1XS
IGR-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUO0eo9yUUN3ME2yNE4{OTF5IN88US=>	NETGd29USU6JRWK=
U-87-MG	NYf1Z5ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETQXJhKSzVyPUKwMlY1OTNizszN	NUDJZmR1W0GQR1XS
NCI-H1304	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7ITWM2OD1{MD63OVAyKM7:TR?=	MlPOV2FPT0WU
RCC10RGB	NFu5eXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHrYSo5KSzVyPUKxMlI5OjlizszN	M1nLd3NCVkeHUh?=
NCI-H520	MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTJ{Lke2NVEh\|ryP	M3zsOHNCVkeHUh?=
SK-LU-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHEeHAyUUN3ME2yN{4xPzF6IN88US=>	NGHJcFNUSU6JRWK=
UACC-893	NX2weY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXPUFFtUUN3ME2yN{4yODN6IN88US=>	NWLZOYxNW0GQR1XS
NCI-H2347	NX3m[JFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzaTWM2OD1{Mz6yOlc1KM7:TR?=	MoX2V2FPT0WU
U-118-MG	NUHoWYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJ\|LkeyNVch\|ryP	NWLvfJVMW0GQR1XS
NCI-H596	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIT0XpdKSzVyPUKzMlkxPTVizszN	MVfTRW5ITVJ?
MZ1-PC	NVzwW\|M{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nwNGlEPTB;MkSuOlc2QSEQvF2=	MV;TRW5ITVJ?
SW1417	NFLPSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJ3LkK0PVgh\|ryP	M3y1TnNCVkeHUh?=
NCI-H82	NYe4dYRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3KzUWlEPTB;Mk[uOFI5QCEQvF2=	NIiwb5JUSU6JRWK=
COLO-678	MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\FNpBKSzVyPUK3MlQ6OTlizszN	M4niSHNCVkeHUh?=
KURAMOCHI	NHrPTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPDPYtFUUN3ME2yPE4yOjZizszN	NXPjO2NzW0GQR1XS
NCI-H1650	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{n2VWlEPTB;M{CuNVkzPCEQvF2=	NYX3TYxpW0GQR1XS
HCC1954	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;ITWM2OD1\|MT6zOlY3KM7:TR?=	MXzTRW5ITVJ?
GAK	NH\qUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGH6OpFKSzVyPUOyMlI3OTZizszN	M4\UcnNCVkeHUh?=
YAPC	NX3GOpdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHtTWM2OD1\|Mz63OlQ5KM7:TR?=	MkTkV2FPT0WU
NCI-H2228	NHzYbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HvXGlEPTB;M{SuN\|YxPSEQvF2=	M4LVU3NCVkeHUh?=
VMRC-RCZ	NYfqZW5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nicGlEPTB;M{[uN\|AzOiEQvF2=	Mlq0V2FPT0WU
NMC-G1	NWfjdWxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTN5LkC1Nlkh\|ryP	Mo\HV2FPT0WU
D-336MG	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XwWmlEPTB;NEGuPFQ1OiEQvF2=	M4P4fHNCVkeHUh?=
UACC-62	M4C5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfZWnZOUUN3ME20Nk42PTB3IN88US=>	MkHtV2FPT0WU
C-33-A	NVHy[IF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jENWlEPTB;NEWuN\|I2PiEQvF2=	NUfrc2x[W0GQR1XS
HCC1937	NFLvVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DGfWlEPTB;NEeuNVk2QCEQvF2=	M{LFdXNCVkeHUh?=
HDLM-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnsfoNKSzVyPUS3MlIzQDdizszN	MljIV2FPT0WU
NCI-H727	NG\2bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfaNYNKSzVyPUS3MlI1PTFizszN	M3HyeHNCVkeHUh?=
NY	MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHMTWM2OD12OT6zPVA5KM7:TR?=	MlO1V2FPT0WU
NCI-H2291	M2PGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTR7LkizNFEh\|ryP	NHr1PGtUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	+ Expand Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order: 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from http://clinicaltrials.gov, updated on 2017-12-12)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01059552	Active, not recruiting	Locally Advanced Non-small Cell Lung Cancer	Fox Chase Cancer Center\|National Comprehensive Cancer Network	December 6, 2009	Phase 1
NCT02108002	Enrolling by invitation	Von Hippel-Lindau Disease	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	March 5, 2014	Phase 1
NCT03022565	Not yet recruiting	Uveal Melanoma	Nicolas Acquavella\|University of Miami Sylvester Comprehensive Cancer Center\|University of Miami	April 2017	--
NCT02943642	Not yet recruiting	Mycosis Fungoides	Angimmune LLC\|City of Hope National Medical Center\|Columbia University\|Dana-Farber Cancer Institute\|Feinberg School of Medicine, Northwestern University\|H. Lee Moffitt Cancer Center and Research Institute\|Ohio State University Comprehensive Cancer Center\|Rush University Medical Center\|Scott and White Hospital & Clinic\|Yale University\|Stanford University\|Thomas Jefferson University\|University of Arkansas\|University of Colorado Denver School of Medicine Barbara Davis Center\|University of Texas Southwestern Medical Center\|University of Washington\|Vanderbilt University School of Medicine\|Washington University School of Medicine	January 2017	Phase 2
NCT02836548	Recruiting	Melanoma\|Skin Neoplasms	The Netherlands Cancer Institute	June 2016	Phase 1\|Phase 2
NCT02589145	Recruiting	Lymphoma	M.D. Anderson Cancer Center\|Celgene Corporation	June 2016	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 HDAC3-selective, IC50=80 nM.

Rocilinostat (ACY-1215) HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
4SC-202 ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 100 Publications

20 Customer Reviews

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from http://clinicaltrials.gov, updated on 2017-12-12)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 100 Publications

20 Customer Reviews

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from http://clinicaltrials.gov, updated on 2017-12-12)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)